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Abstract 
This work aimed at contributing data to help policy makers in planning malaria control 
and adopt policies that might delay the emergence of drug resistance in Sudan. 
A study conducted in a rural area, Gedaref State, eastern Sudan, has examined therapeutic 
efficacies of chloroquine (CQ) Plus dihydroartemisinin (DHA) and CQ plus sulfadoxine-
pyrimethamine (SP) in uncomplicated falciparum malaria. Plasmodium falciparum 
isolates of this area were genotyped for detection of mutations in P. falciparum 
chloroquine transporter (Pfcrt), multidrug resistance (Pfmdr1), dihydrofolate reductase 
(Pfdhfr) and dihydropteroate synthetase (Pfdhps) genes. Polymerase chain reaction (PCR) 
corrected cure rate was comparable in the two treatment arms (CQ + SP, 62.5% [15/24]; 
CQ + DHA, 68.2% [15/22]). The frequency of mutant alleles, Pfdhfr 51I, Pfdhfr 108N, 
Pfdhps 540E, Pfdhps 581G and Pfcrt 76T, Pfmdr1 86Y were; 0.84, 0.84, 0.80 and 0.20, 
0.90, 0.86, respectively. No mutations were detected in positions A16V, C59R and 
I164L, and for Pfdhps loci S436A, A437G and A613S. There was statistically significant 
association between Pfcrt 76T and Pfmdr1 86Y alleles associated with CQ resistance (P 
≤ 0.001), and between Pfdhfr 51I, Pfdhfr 108N and Pfdhps 540E alleles associated with 
SP resistance (P ≤ 0.001–0.04) and all the detected mutations in both CQ and SP 
resistance genes (P = 0.001) except Pfdhps 581G. 
 
Another study in suburban area in Khartoum State has examined therapeutic efficacy of 
SP plus artesunate (AS) in treatment of uncomplicated falciparum malaria. Furthermore, 
polymorphisms associated with SP resistance in Pfdhfr and Pfdhps genes were examined. 
PCR corrected cure rate was 92.6%. Single nucleotide polymorphisms (SNP) were 
detected in positions 51 and 108 Pfdhfr, and positions 436/437, 540 and 581 of Pfdhps. 
The most frequent haplotype was Pfdhfr double mutant haplotype CICNI detected in 
91.9% (N = 79) of the infections, only one infection (1.2%) expressed the wild type 
Pfdhfr haplotype (CNCSI). In contrast Pfdhps mutant haplotypes were found at low rate 
(9.6%), and only two infections (2.2%) had more than one mutation. No significant 
association was observed between the presence of Pfdhfr and/or Pfdhps mutant 
haplotypes and SP plus AS treatment failure.  
 
 VIII
A study in New Halfa and Kassala, eastern Sudan has investigated the distribution of 
Pfdhfr, Pfdhps SP resistance determinant haplotypes. Quintuple mutations at Pfdhfr 
51/59/108 and Pfdhps 437/540 positions were detected for the first time in Sudan (2.9% 
in New Halfa and 5.9% in Kassala). In both study sites the predominant Pfdhfr mutant 
haplotype was the double mutant haplotype (CICNI). Plasmodium falciparum dhfr triple 
mutant haplotype (CIRNI) was identified in New Halfa (2.5%) and Kassala (4.1%). 
Plasmodium falciparum dhps haplotype; harboring 437G and 540E mutations was the 
most frequent mutant Pfdhps haplotype in both sites yielding a percentage of 17.7 in New 
Halfa and 62.5 in Kassala.  
 
Failure to AS plus SP, high frequency of SP resistance marker alleles in different parts of 
the country, in addition to the presence of quintuple mutations in Pfdhfr/Pfdhps genes is 
alarming.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XI 
  :ﺧﻼﺻﺔ اﻟﺪراﺳﺔ
اﻟﻤﻼرﻳѧﺎ ﻟѧﺴﻴﻄﺮة ﻋﻠѧﻰ ﺗѧﺴﻬﻢ ﻓѧﻲ ﻣѧﺴﺎﻋﺪة اﻟﺠﻬѧﺎت اﻟﻤﺨﺘѧﺼﺔ ﻓѧﻲ اﻟﺘﺨﻄѧﻴﻂ ﻋﻠﻤﻴѧﻪ  ﻘﺪﻳﻢ ﻣﻌﻠﻮﻣﺎت ﺘهﺪﻓﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻟ 
  .ﻮﺿﻊ اﺳﺘﺮاﺗﻴﺠﻴﺔ ﻟﻠﻌﻼج ﺗﻬﺪف ﻟﺘﺄﺧﻴﺮ ﻇﻬﻮر اﻟﻤﻼرﻳﺎ اﻟﻤﻘﺎوﻣﺔ ﻟﻸدوﻳﺔ ﻓﻲ اﻟﺴﻮدانﻟ
  
 أﺟﺮﻳѧѧﺖ دراﺳѧѧﺔ ﻓѧѧﻲ رﻳﻔѧѧﻲ ﺷѧѧﺮق اﻟѧѧﺴﻮدان ﻻﺧﺘﺒѧѧﺎر ﻓﻌﺎﻟﻴѧѧﺔ ﺧﻠѧѧﻴﻂ ﻋﻘѧѧﺎري اﻟﻜﻠﻮروآѧѧﻮﻳﻦ  و اﻟﺪاﻳﻬﺎﻳﺪروأرﺗﻴﻤﻴѧѧﺴﻴﻨﻴﻦ
آﻤѧﺎ ﺗﻤѧﺖ . ﻤﻌﻘѧﺪة اﻟﻏﻴѧﺮ   ﻓѧﻲ ﻋѧﻼج اﻟﻤﻼرﻳѧﺎ )PS+QC(  و ﺧﻠﻴﻂ ﻋﻘﺎري اﻟﻜﻠﻮروآﻮﻳﻦ و اﻟﻔﺎﻧѧﺴﻴﺪار )AHD+QC(
آﺎن ﻣﺴﺘﻮى .   ﻟﺠﻤﻴﻊ اﻟﻌﻴﻨﺎت اﻟﺘﻲ ﺟﻤﻌﺖ ﻗﺒﻞ ﺑﺪاﻳﺔ اﻟﻌﻼجsphdfP   و  rfhdfP ،   1rdmfP،trcfPﻃﺒﺎﻋﺔ ﺟﻴﻨﺎت 
( etar eruc noitcerroc RCP)ﻟﺴﻠѧﺴﻠﻲ اﻟﻤﺘﺒﻠﻤѧﺮ اﻻﺳﺘﺠﺎﺑﺔ ﻟﻨﻮﻋﻲ اﻟﻌѧﻼج ﺑﻌѧﺪ اﻟﺘѧﺼﺤﻴﺢ ﺑﺎﺳѧﺘﻌﻤﺎل ﺗﻘﻨﻴѧﺔ اﻟﺘﻔﺎﻋѧﻞ ا 
  trcfPآﺎﻧﺖ ﻧѧﺴﺒﺔ وﺟѧﻮد اﻟﻄﻔѧﺮات اﻷﻟﻴﻠﻴѧﺔ،  . PS+QC  ﻟﺨﻠﻴﻂ  %5.26  و AHD+QC ﻟﺨﻠﻴﻂ %2.86ﻣﺘﻘﺎرب،  
، %68، %09 : G185 sphdfP و E045 sphdfP، N801 rfhdfP، I15 rfhdfP، Y68 1rdmfP، T67
 و 461، 95، 61ﻓѧﻲ اﻟﻤﻮاﻗѧﻊ  rfhdfP أي ﻃﻔﺮات ﻓﻲ اﻟﺠﻴﻦ  ﺟﺪﺗﻮﻟﻢ و .  ﻋﻠﻰ اﻟﺘﻮاﻟﻲ%02 و %08، %48، %48
  .316، 734، 634ﻓﻲ اﻟﻤﻮاﻗﻊ  sphdfPﻓﻲ اﻟﺠﻴﻦ 
ﻟѧѧﻮﺣﻆ وﺟѧѧﻮد ﻋﻼﻗѧѧﺔ ذات دﻻﻟѧѧﺔ اﺣѧѧﺼﺎﺋﻴﺔ ﺑѧѧﻴﻦ وﺟѧѧﻮد اﻟﻄﻔѧѧﺮات اﻷﻟﻴﻠﻴѧѧﺔ اﻟﻤﺮﺗﺒﻄѧѧﺔ ﺑﻤﻘﺎوﻣѧѧﺔ ﻃﻔﻴѧѧﻞ اﻟﻤﻼرﻳѧѧﺎ ﻟﻌﻘѧѧﺎر 
 اﻟﻤﺮﺗﺒﻄﺔ ﺑﻤﻘﺎوﻣﺔ اﻟﻄﻔﻴѧﻞ ﻟﻌﻘѧﺎر ﻟﻴﻠﻴﺔاﻟﻄﻔﺮات اﻷو ﺑﻴﻦ ( 100.0 ≤ P )Y68 1rdmfP وT67 trcfPاﻟﻜﻠﻮروآﻮﻳﻦ، 
و ﺑѧﻴﻦ وﺟѧﻮد آѧﻞ اﻟﻄﻔѧﺮات ( 40.0-100.0 ≤P )E045 sphdfP و N801 rfhdfP و I15 rfhdfPﺪار، ﻴاﻟﻔﺎﻧѧﺴ 
  .    G185 sphdfPﻣﺎ ﻋﺪا ( 100.0 = P)اﻷﻟﻴﻠﻴﺔ اﻟﺘﻲ ﺗﻢ اﻳﺠﺎدهﺎ 
  
 ﻓѧﻲ ﻣﻨﻄﻘѧﻪ ﺷѧﺒﻪ ﻤﻌﻘѧﺪة اﻟﻏﻴѧﺮ ﻤﻼرﻳѧﺎ  ﻓѧﻲ ﻋѧﻼج اﻟ )PS+SA( ﻓﻌﺎﻟﻴﺔ ﺧﻠѧﻴﻂ ﻋﻘѧﺎري اﻟﻔﺎﻧѧﺴﻴﺪار و اﻷرﺗﻴѧﺴﻴﻨﻴﺖ تاﺧﺘﺒﺮ
اﻟﻤﺮﺗﺒﻄѧﺔ ﺑﻤﻘﺎوﻣѧﺔ ﻃﻔﻴѧﻞ اﻟﻤﻼرﻳѧﺎ ﻟﻠﻔﺎﻧѧﺴﻴﺪار   ﻴﺔ أﺧﺮى ﺗﻢ ﺗﺤﺪﻳѧﺪ اﻟﻄﻔѧﺮات اﻷﻟﻴﻠﻴѧﺔ و ﻣﻦ ﻧﺎﺣ . ﻮﻻﻳﺔ اﻟﺨﺮﻃﻮم ﺣﻀﺮﻳﻪ ﺑ 
آﺎن ﻣﻌﺪل اﻻﺳﺘﺠﺎﺑﺔ اﻟﺪوااﺋﻴﺔ ﺑﻌﺪ اﻟﺘﺼﺤﻴﺢ ﺑﺎﺳﺘﻌﻤﺎل ﺗﻘﻨﻴﺔ اﻟﺘﻔﺎﻋﻞ اﻟﺴﻠﺴﻠﻲ  . ﺑﺎﻟﻤﻨﻄﻘﺔ sphdfPو  rfhdfPﻓﻲ ﺟﻴﻨﺎت 
 801 و 15 اﻟﻄﻔѧﺮات ﻓѧﻲ اﻟﻤﻮاﻗѧﻊ  ووﺟѧﺪت rfhdfP ﻓѧﻲ اﻟﺠѧﻴﻦ .%6.29( etar eruc noitcerroc RCP)اﻟﻤﺘﺒﻠﻤѧﺮ 
آﺎﻧѧﺖ أآﺜѧﺮ اﻷﻧﻤѧﺎط اﻟﻔﺮداﻧﻴѧﺔ ﻟﻠﺠѧﻴﻦ . 185 و 045 و 734/634 ﻓѧﻲ اﻟﻤﻮاﻗѧﻊ sphdfP ﻓѧﻲ اﻟﺠѧﻴﻦ وﺟѧﺪتﻓﻘѧﻂ، ﺑﻴﻨﻤѧﺎ 
 199.%ﻓѧﻲ وﺟﺪ اﻟﺬي (  CICNI )801 و 15 وﺟﻮدا ﻓﻲ اﻟﻤﻨﻄﻘﺔ هﻮ اﻟﻨﻤﻂ ذو اﻟﻄﻔﺮات اﻟﺜﻨﺎﺋﻴﺔ ﻓﻲ اﻟﻤﻮاﻗﻊ rfhdfP
ﻓѧﻲ ﻋﻴﻨѧﺔ واﺣѧﺪة ﻓﻘѧﻂ ( ISCNC )rfhdfPﻣﻦ اﻟﻌﻴﻨﺎت اﻟﺘѧﻲ ﺗѧﻢ اﺧﺘﺒﺎرهѧﺎ، ﺑﻴﻨﻤѧﺎ وﺟѧﺪ اﻟѧﻨﻤﻂ اﻟﻔﺮداﻧѧﻲ اﻟﻄﺒﻴﻌѧﻲ ﻟﻠﺠѧﻴﻦ 
و ﻗﺪ ﻟѧﻮﺣﻆ وﺟѧﻮد ( %6.9) ﺑﻤﻌﺪل ﻗﻠﻴﻞ ﻓﻲ اﻟﻤﻨﻄﻘﺔ sphdfPوﺟﺪت اﻷﻧﻤﺎط اﻟﻔﺮداﻧﻴﺔ ذات اﻟﻄﻔﺮات ﻟﻠﺠﻴﻦ (. %2.1)
ﻟﻢ ﻳﻼﺣﻆ وﺟﻮد أي ﻋﻼﻗѧﺔ ذات دﻻﻟѧﺔ (. %2.2)ﻣﻦ ﻃﻔﺮة أﻟﻴﻠﻴﺔ واﺣﺪة ﻓﻲ ﻋﻴﻨﺘﻴﻦ ﻓﻘﻂ اﻟﻨﻤﻂ اﻟﻔﺮداﻧﻲ اﻟﺬي ﻳﺤﻤﻞ أآﺜﺮ 
ﺪار و ﻣﺨﺘﻠﻒ اﻷﻧﻤﺎط اﻟﻔﺮداﻧﻴﺔ ذات اﻟﻄﻔﺮات ﻓﻲ اﻟﺠﻴﻨﺎت ﻴاﺣﺼﺎﺋﻴﺔ ﺑﻴﻦ اﻻﺳﺘﺠﺎﺑﺔ ﻟﺨﻠﻴﻂ ﻋﻘﺎري اﻷرﺗﻴﺴﻴﻨﻴﺖ و اﻟﻔﺎﻧﺴ 
  .    أو ﻓﻲ اﻟﺠﻴﻨﻴﻦ ﻣﺠﺘﻤﻌﻴﻦsphdfP أو  rfhdfP
  
ﺪار ﻓѧѧﻲ ﻴ اﻟﻤﺮﺗﺒﻄѧѧﺔ ﺑﻤﻘﺎوﻣѧѧﺔ ﻃﻔﻴѧѧﻞ اﻟﻤﻼرﻳѧѧﺎ ﻟﻠﻔﺎﻧѧѧﺴ sphdfPو  rfhdfPﺮداﻧﻴѧѧﺔ ﻟﺠﻴﻨѧѧﻲ ﺗﻤѧѧﺖ دراﺳѧѧﺔ ﺗﻮزﻳѧѧﻊ اﻷﻧﻤѧѧﺎط اﻟﻔ 
ﺪ اﻟѧﻨﻤﻂ ﺧﻤﺎﺳѧﻲ اﻟﻄﻔѧﺮات اﻷﻟﻴﻠﻴѧﺔ ﻓѧﻲ وﺟѧ و ﻷول ﻣѧﺮة ﻓѧﻲ اﻟѧﺴﻮدان . ﻣﻨﻄﻘﺘﻲ ﺣﻠﻔﺎ اﻟﺠﺪﻳﺪة و آﺴﻼ ﻓѧﻲ ﺷѧﺮق اﻟѧﺴﻮدان 
X 
 %9.5اﻟﺠﺪﻳѧﺪة و  ﻓѧﻲ ﺣﻠﻔѧﺎ %9.2 ﺑﻨѧﺴﺒﺔ sphdfPﻟﻠﺠѧﻴﻦ  045/634 و اﻟﻤﻮاﻗѧﻊ rfhdfP ﻟﻠﺠﻴﻦ 801/95/15اﻟﻤﻮاﻗﻊ 
ﻓѧﻲ آѧﻞ ﻣѧﻦ ﻣﻨﻄﻘﺘѧﻲ اﻟﺪراﺳѧﺔ هѧﻮ اﻟѧﻨﻤﻂ  وﺟѧﻮدا rfhdfPآѧﺎن أآﺜѧﺮ اﻷﻧﻤѧﺎط اﻟﻔﺮداﻧﻴѧﺔ ذات اﻟﻄﻔѧﺮات ﻟﻠﺠѧﻴﻦ . ﻓﻲ آﺴﻼ 
 و 95 و 15اﻟﻨﻤﻂ اﻟﻔﺮداﻧѧﻲ ﺛﻼﺛѧﻲ اﻟﻄﻔѧﺮات ﻓѧﻲ اﻟﻤﻮاﻗѧﻊ (. CICNI )801 و 15اﻟﻔﺮداﻧﻲ ﺛﻨﺎﺋﻲ اﻟﻄﻔﺮات ﻓﻲ اﻟﻤﻮاﻗﻊ 
و ﻗѧﺪ آѧﺎن أآﺜѧﺮ .  ﻋﻠѧﻰ اﻟﺘѧﻮاﻟﻲ 41.% و 25.%ﺠﺪﻳﺪة  و آﺴﻼ ﺑﻨѧﺴﺒﺔ وﺟﺪ ﻓﻲ ﺣﻠﻔﺎ اﻟ ( CNRII )rfhdfP ﻟﻠﺠﻴﻦ 801
 ا ﻓﻲ آﻞ ﻣﻦ ﻣﻨﻄﻘﺘﻲ اﻟﺪراﺳﺔ هﻮ اﻟﻨﻤﻂ اﻟﻔﺮداﻧﻲ ﺛﻨﺎﺋﻲ اﻟﻄﻔﺮات  وﺟﻮدا sphdfPاﻷﻧﻤﺎط اﻟﻔﺮداﻧﻴﺔ ذات اﻟﻄﻔﺮات ﻟﻠﺠﻴﻦ 
  . ﻓﻲ آﺴﻼ265.% ﻓﻲ ﺣﻠﻔﺎ اﻟﺠﺪﻳﺪة و 717.%ﺣﻴﺚ وﺟﺪ ﺑﻨﺴﺒﺔ ( SEGAA )045 و 734ﻓﻲ اﻟﻤﻮاﻗﻊ 
  
، و وﺟѧﻮد اﻟﻄﻔѧﺮات ار ﻟﺨﻠѧﻴﻂ ﻋﻘѧﺎري اﻷرﺗѧﺴﻴﻨﻴﺖ و اﻟﻔﺎﻧѧﺴﻴﺪ اﻟﻌﻼﺟѧﻲاﻟﻔѧﺸﻞ ﺋﺞ هѧﺬﻩ اﻟﺪراﺳѧﺔ و اﻟﺘѧﻲ ﺗѧﺸﻤﻞ  ﻧﺘѧﺎﺗﻤﺜѧﻞ
 اﻟѧﻨﻤﻂ ﺑﺎﻻﺿѧﺎﻓﺔ ﻟﻮﺟѧﻮد    ﻓѧﻲ ﻣﻨѧﺎﻇﻖ ﻣﺨﺘﻠﻔѧﺔ ﺑﺎﻟѧﺴﻮدان  ﺑﻤﻌﺪل ﻋѧﺎﻟﻲ اﻷﻟﻴﻠﻴﺔ اﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻔﺸﻞ اﻟﻌﻼﺟﻲ ﻟﻌﻘﺎر اﻟﻔﺎﻧﺴﻴﺪار 
   .ﻣﺆﺷﺮا ﺧﻄﻴﺮا ﻷول ﻣﺮة ﺑﺎﻟﺴﻮدانﻣﻌﺎ  sphdfP و اﻟﺠﻴﻦ rfhdfP ﺧﻤﺎﺳﻲ اﻟﻄﻔﺮات اﻷﻟﻴﻠﻴﺔ ﻓﻲ اﻟﺠﻴﻦ اﻟﺠﻴﻨﻲ
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 1
1. Introduction and Literature Review 
1.1. General introduction 
Malaria is a complex public health problem in the African continent. It presents an 
enormous obstacle to national development because of its high human and economic 
costs. Malaria is a mosquito borne disease caused by the protozoan falciparum, five 
species of which infect humans. These are Plasmodium falciparum (P. falciparum), P. 
vivax, P. ovale, P. malariae and P. knowlesi. Malaria is an important cause of 
morbidity and mortality in children and adults in tropical countries, almost all deaths 
and severe disease are caused by P. falciparum (1). The vector responsible for malaria 
transmission is the female Anophelene mosquito. There are over 40 species of 
anopheline mosquitoes that transmit human malaria, which differ in their transmission 
potential. The most competent and efficient malaria vector, Anopheles gambiae (A. 
gambiae), occurs exclusively in Africa (2).  However, despite enormous and diverse 
efforts to control the disease, malaria is among the top three most deadly 
communicable diseases and the most deadly tropical parasitic disease today (3).   
1.2. Global malaria burden 
Malaria has a worldwide distribution, being found in tropical areas, throughout sub 
Saharan Africa and to a lesser extent in South Africa, Southeast Asia (SE Asia), the 
Pacific islands, India and Central and South America (1). Falciparum is the 
predominant species in most endemic countries, and is most prevalent in Africa south 
of the Sahara and in certain areas of SE Asia and the Western Pacific. The second 
most common malaria species, P. vivax, is rarely fatal and commonly found in most 
of Asia, and in parts of the Americas, Europe and North Africa (2). Plasmodium ovale 
is mainly found in West Africa. It is found in SE Asia, particularly along the borders 
of Thailand with Myanmar and Cambodia (1). 
Furthermore, the disease burden falls disproportionately on vulnerable groups; 
including pregnant women and children under five, who have limited access to 
malaria control interventions, which perpetuates a vicious cycle of poverty and 
disease. 
At the end of 2004, 107 countries and territories had areas at risk of malaria 
transmission. Some 3.2 billion people lived in areas at risk of malaria transmission 
(2), estimated incidence totaled 402 million (range 350-500 million) cases (4), 
resulting in over 1 million deaths. The estimated mortality rate has risen in recent 
years, probably due to increasing resistance to antimalarial medicines (5). About 59% 
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of the world’s clinical malaria cases occur in Africa, around 38% in Asia and around 
3% in the Americas, for falciparum malaria specifically, the estimated regional 
distribution is around 74% in Africa, 25% in Asia and around 1% in the Americas (2). 
About 90% of malaria deaths occur in Africa south of the Sahara, 90% of all malaria 
deaths in Africa occur in young children (6). In Africa young children and pregnant 
women are the population groups at highest risk for malaria morbidity and mortality. 
The disease takes an economic toll as well because of reduced productivity, which is 
responsible for an estimated average loss of 1.3% of economic growth annually in 
countries with intense transmission for those countries with the highest burden (7).  
Patterns of malaria transmission vary markedly between regions and even within an 
individual country. This diversity results from variations between malaria parasites 
and mosquito vectors, ecological conditions that affect malaria transmission and 
socioeconomic factors, such as poverty and access to effective health care and 
prevention services. As a result of differing intensities of malaria transmission, the 
population groups at risk of malaria also differ between world regions. 
1.3.Malaria infection 
Malaria infection manifests itself in different ways; it can be asymptomatic or present 
with various uncomplicated (mild) or severe forms. 
Asymptomatic malaria occurs in areas of constant and high transmission, where 
malaria immunity develops rapidly. It is characterized by the presence of asexual 
blood stage parasites in the peripheral blood without obvious outward signs of 
infection. Asymptomatic infections contribute to further transmission, and may also 
affect the overall health status of the individual by contributing to anaemia and/or 
weakening the individual’s ability to fight off other infections, this is common in 
intense malaria transmission areas (8,9,10). Uncomplicated malaria (non severe) 
presenting with vague symptoms before the development of acute paroxysms of high 
fever and chills, which in a proportion of cases may progresses to severe malaria 
requiring hospitalization (8). Almost all severe forms of malaria are caused by P. 
falciparum but rarely P. vivax or P. ovale produce serious complications, debilitating 
relapses and even death (11).    
1.4. Malaria diagnosis 
Conventional diagnosis still uses the skilled but laborious and time consuming 
microscopic examination of thin and thick blood films stained with Giemsa’s or 
Field’s stain. Newly developed tests include the quantitative buffy coat (QBC)  
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method for the fluorescent staining of parasites after an enrichment step for the 
infected erythrocyte; it is reported to be as good as thick films for P. falciparum but 
not for the other species (12); the ParaSight F (13) and the Malaquick tests (14) based 
on the immunological capture of the P. falciparum histidine-rich protein 2 in whole 
blood; and the OptiMal assay, which is antibody based detection of parasite lactate 
dehydrogenase (15). These antibody based dipstick tests are still being evaluated. 
Polymerase chain reaction (PCR) based diagnostic tests for human malarias have been 
developed (16), but these are more applicable to large scale surveys than to clinical 
diagnosis. Polymerase chain reaction has been especially effective at detecting sub 
microscopic levels of parasitemia (17,18). 
1.5. Malaria control and prevention 
The world’s malaria situations can be divided into three categories (19). First category 
represent areas with intense malaria transmission which have largely been unaffected 
by vector control programs, such as tropical Africa. Second, are areas where large 
scale vector control programs have been operating, which represent the malaria 
situation in most malarious countries in Asia and the Americas. Areas of rapid 
economic development and countries seriously affected by social disruption are 
placed into the third category. No single strategy is applicable for all situations 
because characteristics of the malaria disease differ from country to country and even 
within the same country.  
Malaria control efforts in recent years have contributed substantially to the 
availability of cost effective tools that can be used by endemic African countries. 
These tools are directed towards control of mosquito vector such as reducing breeding 
sites, insecticides, insecticide treated nets (ITNs) and indoor residual spraying (IRS) 
(20,21). Other approaches are directed at controlling the parasites in the human host 
which include efficacious artemisinin based combination therapies (ACTs) (22), 
Malaria Early Warning Systems (MEWS) to detect and contain outbreaks, 
intermittent preventive treatment in infant (IPTi) and during pregnancy (IPTp) (23; 
24). 
1.6. Malaria parasite 
1.6.1. The life cycle of malaria parasite 
All stages in the life cycle of the Plasmodium parasite are haploid, apart from the 
diploid zygote, which immediately after fertilization undergoes meiosis to yield 
haploid infectious forms (25). The life cycle of Plasmodium parasites which affect 
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human involves two hosts; vertebrate and invertebrate host, have sexual and asexual 
stages (1) (Figure 1.1).  
Plasmodium falciparum sporozoites are released from the female mosquito’s salivary 
glands into the blood stream of the vertebrate host, and within minutes it reach the 
liver and start to reproduce, mature into hepatic schizonts which subsequently rupture, 
releasing merozoites. It takes the parasite one to two weeks to mature during the liver 
stage (pre erythrocytic stage). During the pre erythrocytic stage an infected person 
shows no signs or symptoms of disease, and malaria can not be detected.  
The merozoites which are haploid are released into the blood stream and rapidly 
infect red blood cells to start the erythrocytic stage. They begin cycles of invading red 
blood cells, multiplying, and rupturing every 48 hours for falciparum, vivax and ovale 
malarias and 72 hours for P. malariae. It only takes a few seconds for merozoites to 
invade new blood cells, so merozoites spend much of the time inside them, protected 
from the immune system. During the blood stage, that infected persons develop the 
periodic fevers, chills, and other signs of malaria. 
After a number of asexual life cycles, some of the merozoites mature into sexual 
forms (gametocytes), gametocyte production takes approximately 10 days in 
falciparum malaria compared to only 4 days in vivax malaria. When a female 
anophelene mosquito, during a blood meal, takes up these sexual forms, they fuse in 
the midgut to form a zygote (a transient diploid form), which then undergoes meiosis 
to yield new haploid infectious forms (sporozoites), and completes the life cycle. The 
parasite is then poised to begin the cycle again with the mosquito’s next blood meal. 
In vivax and ovale malarias a number of the sporozoites arriving at the liver become 
dormant hypnozoites, capable of causing a relapse of malaria at a later date. P. 
malariae does not have the hypnozoite stage but may persist in the blood for many 
years if inadequately treated (26). 
1.6.2. Genetics of Plasmodium falciparum 
The complete genome sequence of P. falciparum clone 3D7 was published in 2002 
(27). The 23 mega base nuclear genome consists of 14 chromosomes ranging in size 
from approximately 0.643 to 3.29 Mb, encodes about 5,300 genes with an (A + T) 
content of 80.6%, and rises to ≈ 90% in introns and intergenic regions. Compared to 
the genomes of free living eukaryotic microbes, the genome of this intracellular 
parasite encodes fewer enzymes and transporters, but a large proportion of genes are 
devoted to immune evasion and host parasite interactions.  
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Figure 1.1: The life cycle of Plasmodium falciparum parasite 
Reproduced from www.malariavaccine.org 
 
 
 
 
 
 
 
 
 6
Many nuclear encoded proteins are targeted to the apicoplast, an organelle involved in 
fatty acid and isoprenoid metabolism. Plasmodium falciparum chromosomes vary 
considerably in length, with most of the variation occurring in the subtelomeric 
regions. Field isolates, even those from individuals residing in a single village (28), 
 exhibit extensive size polymorphism that is thought to be due to recombination 
events between different parasite clones during meiosis in the mosquito (29). About 
60% of the predicted proteins appear to be unique to this organism, a proportion much 
higher than observed in other eukaryotes. 
1.6.3. Antigenic determinant genes in malaria parasites 
Plasmodium falciparum exhibits antigenic polymorphisms. Numerous polymorphic 
antigens of the asexual stages of P. falciparum are now well characterized. Parasite 
surface proteins of the sporozoite (CSP, coding for the circumsporozoite protein) and 
the merozoite (MSP-1 and MSP-2, coding for the merozoite surface proteins 1 and 2) 
are known to be extremely polymorphic. Genes coding for these antigenic proteins; 
have been found to be highly polymorphic and that their multiple allelic forms differ 
in their ability to escape the host’s immune response (30–32).  
1.6.3.1. Merozoite surface proteins 1 (MSP-1) 
The MSP-1 gene located on chromosome 9, codes for MSP-1, previously referred to 
as P195, gp185, PSA, or PMMSA (34). The MSP-1 is a glycoprotein (≈195 kilo 
Dalton) that is processed at the time of schizont rupture to generate several smaller 
polypeptides on the mature merozoite surface (33). 
Tanabe et al. (34) partitioned MSP-1 into 17 blocks, based on the degree of amino 
acid polymorphism. They classified seven blocks (blocks 2, 4, 6, 8, 10, 14, and 16) as 
highly variable; five blocks (blocks 7, 9, 11, 13, and 15) as semi conserved, and five 
blocks (blocks 1, 3, 5, 12, and 17, which include the two terminal segments) as 
conserved. Block 2 region, located within the N-terminal half of MSP-1, is highly 
polymorphic, with different sequence variants identified.  
All sequence variant on block 2 of MSP1 belong to one or another of only three main 
sequence types represented by variants originally identified in the K1, MAD20, and 
RO33 isolates (35). Variants within the K1-like and MAD20-like types of block 2 
differ in tri- or hexapeptide repeats (34,35,36), whereas block 2 of the RO33 type is a 
nonrepetitive sequence which varies little between isolates (36). 
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1.6.3.2. Merozoite surface proteins 2 (MSP-2) 
The Msp-2 gene located in chromosome 2, codes for MSP-2 (or MSA-2), which is a 
glycoprotein, a smaller polypeptide of 45 kilo Dalton that is not processed during 
parasite maturation but, like MSP-1, appears to be anchored in the merozoite 
membrane by a glycosylphosphatidylinositol moiety (37). 
Studies of the genes from P. falciparum isolates (38,39) revealed that MSP-2 contains 
highly conserved N and C termini, with 43 and 74 residues, respectively. Bracketed 
within these conserved regions, is the highly variable repeat region. The MSP-2 of 
isolate FCQ27/PNG (FC27) contains two copies of a 32 amino acid repeat, whereas 
the Msp-2 of Indochina 1 (IC1) and 3D7 contain multiple copies of a 4 amino acid 
sequence with no apparent relationship to the FC27 repeat. Variant sequences are 
flanking the repeats.  
The polymorphism at MSP-1 and MSP-2 loci are mainly assessed by the number of 
repeats (38,40), which can be used to distinguish the different alleles by size after 
amplification by PCR. 
1.7. Chemotherapy of malaria 
Recommendations for treatment of malaria vary according to geographic region 
because it depends on the severity of the infection, the patient’s age, the degree of 
background immunity, effectiveness of antimalarial drugs, and the cost and 
availability of such drugs.  
The antimalarials in common use come from five classes of compounds; the 
quinolines and arylaminoalcohols, the antifols, the artemisinin (ART) derivatives, the 
hydroxynaphthaquinones and antibacterial agents (1). 
1.7. 1. Quinoline containing drugs 
The quinoline containing drugs include the 4-aminoquinolines, chloroquine (CQ) and 
its relative amodiaquine, the cinchona alkaloids, quinine and quinidine, and the 
aminoalcohol mefloquine (a 4-quinoline methanol) and halofantrine (a 9-phenathrene 
methanol). There are also the 8-aminoquinoline primaquine, in addition to 
lumefantrine, piperaquine, pyronaridine. 
Chloroquine is a 4-aminoquinoline which has been used for treatment and prevention 
of malaria. Chloroquine is characterized by long elimination half life (1-2 months) 
(5). It is cheap, and was reported as the most widely consumed drug in the world after 
aspirin and paracetamol (41).  
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Amodiaquine is a Mannich base 4-aminoquinoline with a mode of action similar to 
that of CQ. It is more active than CQ against resistant parasites. There are insufficient 
data on its terminal plasma elimination half life (5).  
Quinine, an alkaloid derived from the bark of the cinchona tree (42). The mean 
elimination half life is around 11 hours in healthy subjects, 16 in uncomplicated 
malaria and 18 in severe malaria (43). Quinine is combined with an antibiotic such as 
tetracycline/doxycycline or clindamycin to treat falciparum malaria infections in 
regions where sensitivity to quinine is reduced (44), and is reserved for cases of 
severe malaria. 
Quinidine is related to quinine and is used intravenously to treat severe malaria (1). 
Mefloquine is a 4-methanolquinoline compound, effective against all forms of malaria 
(5). It has a long elimination half life of around 21 days, which is shortened in malaria 
to about 14 days, possibly because of interrupted enterohepatic cycling (45). The use 
of mefloquine is contraindicated in patients with epilepsy, a history of 
neuropsychiatric disease or in patients recovering from cerebral malaria. It should not 
be given to treat patients who have already received the drug in the preceding 4 weeks 
or whose ability to work safely may be impeded by drug side effects. As a treatment it 
should be combined with 3 days of artesunate (46). A fixed co-formulation of the two 
medicines is under development.  
Primaquine is an 8-aminoquinoline and is effective against intrahepatic forms of all 
types of malaria parasites. It is used for the treatment of P. vivax and P. ovale malaria 
(5). Its elimination half life is 3-6 hours (47).  Primaquine has potent gametocytocidal 
properties against P. falciparum. It is contraindicated in pregnancy or in individuals 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it may cause massive 
haemolysis (48).  
Lumefantrine is a racemic 2, 4, 7, 9-substituted fluorine derivative synthesised in 
China. It is manufactured as a fixed combination with artemether. Lumefantrine 
absorption is dependent on co-administration with fat. Each dose should be taken with 
a fatty meal or with 200 ml milk (49). The terminal elimination half life is around 3 
days (5).  
Piperaquine is a bisquinoline compound related to CQ. It has been co-formulated with 
dihydroartemisinin (DHA) as a fixed dose combination that has been registered in a 
number of Asian countries in recent years. Experience with the drug suggests its 
effectiveness and safety for the treatment of uncomplicated falciparum malaria (50).  
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Tafenoquine is a promising new 8-aminoquinoline which is still in phase III trials for 
the eradication of hypnozoites. It has a much longer half life than primaquine. It is 
also contraindicated in patients with G6PD deficiency (1).  
Pyronaridine which is a Mannich base compound developed in China has been 
combined with artesunate in a new fixed combination which is in phase II clinical 
trials. Reported adverse events after treatment with the combination were mild and 
transient (51).  
1.7. 2. Antifolate drugs 
The Antifolates (folate biosynthesis inhibitors) include the diaminopyrimidines, such 
as pyrimethamine and trimethoprim; the biguanides, represented by proguanil 
(cycloguanil) and chlorproguanil; and the sulfa drugs, including the sulfonamides and 
the sulfones. A marked synergy between sulfa drug types and pyrimethamine or 
proguanil was discovered in the 1960s, the most frequently used combinations being 
sulfadoxine-pyrimethamine (SP) (Fansidar) and pyrimethamine-dapsone (Maloprim) 
(52). The latest addition to this class is the fixed combination chlorproguanil-dapsone 
(LapdapTM), it is thought to be more effective than SP against P. falciparum in Africa 
(53). 
1.7. 3. Artemisinin derivatives 
Artemisinin which is known as qinghaosu in china, was isolated from the leaves of 
Artemisia annua (sweet wormwood plant) in 1972 (54). It has been used in traditional 
Chinese medicine for centuries as a treatment of fever (55). Artemisinin itself is 
poorly absorbed, and therefore semisynthetic derivatives have been used; A water 
soluble compound; artesunate (AS); is a hemisuccinate ester of ART exists as oral, 
suppository, intramuscular and intravenous forms; and it can be considered a prodrug 
for DHA. In addition two oil soluble compounds are available; artemether which is 
the methyl ether of DHA which is available in oral and intramuscular preparations 
and arteether (Artemotil) which is the ethyl ether of ART, given by intramuscular 
injection only. Dihydroartemisinin; the main active metabolite of the ART derivatives 
can be given orally or rectally as a drug in its own right. Artemisinin compounds are 
active against different species of plasmodium that infect humans (56,57,58). They 
exhibit a rapid action and high efficacy against the blood stages of Plasmodium, 
including the youngest stages (ring forms) (59), and have been shown to reduce the 
number of gametocytes in the blood (60,61). Artemisinins also decrease the 
infectivity of gametocytes to mosquitoes (62,63). This property may help reduced 
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transmission rates in areas of low transmission (64), but it has no benefit in areas of 
high transmission despite reported reduction of gametocyte rate (65,66). Artemisinin 
derivatives are characterized by a short half life (67). High rate of recrudescence 
associated with ART monotherapy, and the attendant risk of the development of drug 
resistance was reported (68,69). Clinical failure caused by ART resistant P. 
falciparum has not yet been reported. The main concern with the lipid soluble 
derivatives is related to their toxicity in animals (70), but similar toxicity has not 
become an issue with humans.  
1.7. 4. Hydroxynaphthaquinones 
Hydroxynaphthaquinones represented by atovaquone which is used in a fixed 
combination with proguanil (MalaroneTM) for malaria prophylaxis and treatment (1). 
Resistance develops rapidly after atovaquone monotherapy (71). 
1.7. 5. Antibacterial drugs 
Antibacterial drugs with antimalarial activity are clindamycin, tetracycline, 
doxycycline which is used for chemoprophylaxis in travelers and azithromycin which 
is closely related to erythromycin. Antibiotics are weak antimalarials and slow acting 
and should not be used as monotherapy to treat malaria (5). The tetracyclines in 
combination with quinine or ART derivatives may be used for the treatment of 
falciparum malaria but they are contraindicated in young children and pregnancy (5). 
Antimalarials which are easily affordable by many malaria endemic countries are 
restricted to CQ, SP, quinine, amodiaquine and mefloquine in SE Asia, ART 
derivatives are increasingly used throughout tropical world (72). 
1.7. 6. Criteria for antimalarial treatment policy change 
In 2006 World Health Organization (WHO) recommended that antimalarial treatment 
policy should be changed at treatment failure rates considerably lower than those 
recommended previously. It has been recommended that a change of first line 
treatment should be initiated if the total failure proportion exceeds 10% (5). However, 
it is acknowledged that a decision to change may be influenced by a number of 
additional factors, including the prevalence and geographical distribution of reported 
treatment failures, health service provider and/or patient dissatisfaction with the 
treatment, the political and economical context, and the availability of affordable 
alternatives to the commonly used treatment (5). 
 
 
 11
1.8. Resistance to antimalarial drugs 
Antimalarial drug resistance is defined as the ability of a parasite strain to survive 
and/or multiply despite the proper administration and absorption of an antimalarial 
drug in the dose normally recommended (5). Malaria treatment failure is a failure to 
clear malarial parasitaemia and/or resolve clinical symptoms despite the 
administration of an antimalarial. So while drug resistance may lead to treatment 
failure, not all treatment failures are caused by drug resistance (5).  
The emergence of antimalarial drug resistance has increased the global malaria 
burden and is a major threat to malaria control. Resistant falciparum malaria has been 
a major contributor to the global resurgence of malaria in the last three decades (73). 
The clinical consequences of antimalarial drug resistance are well described in terms 
of increased morbidity and mortality, especially amongst young African children 
(74,75).  
Resistance to antimalarials has been documented for P. falciparum, P. vivax and, 
recently, P. malariae. In P. falciparum, resistance has arisen to all classes of 
antimalarials except, as yet, to the ART derivatives.  
1.8.1. Global distribution of antimalarial drug resistance 
First reports of CQ resistance appeared in 1957 and more significant reports appeared 
in 1961 (76). The first report of resistance to proguanil appeared in 1950, 
pyrimethamine in 1953, SP in 1967, mefloquine in 1983, quinine in 1987, and 
amodiaquine in 1988 (77). Plasmodium falciparum resistance to CQ and SP is 
widespread. There are also foci of mefloquine, halofantrine and amodiaquine 
resistance (78).  
Chloroquine has had a reasonable period of effective deployment. Chloroquine 
resistance has been reported from wherever falciparum malaria is endemic, except 
Central America and the Caribbean (78). Recent molecular studies favour importation 
of chloroquine resistance to Africa from East Asia  (79,80).  
The first reports of possible quinine resistance occurred in Brazil almost 100 years 
ago. Clinical resistance to quinine is reported sporadically in SE Asia and western 
Oceania, and resistance in Africa and South America is much less frequent (5). In 
vitro studies suggested quinine resistance in South America (81) and Africa (82).  
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Figure 1.2: Malaria transmission areas and the distribution of reported 
resistance or treatment failures with selected antimalarial drugs, September 
2004. Reproduced from WHO, 2006 [5]  
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Resistance to mefloquine is confined to those areas where it has been used widely 
(Thailand, Cambodia and Vietnam) (83). It was first reported in the late 1980s (84) 
near the Thai Cambodian border. Migrant gem-miners returning from Cambodia may 
have been the means of the spread of mefloquine resistance to Bangladesh and India 
(85). The level of resistance to mefloquine in South America is lower than in SE Asia, 
there are also case reports of mefloquine resistance from the Amazon Basin (78), but. 
Low mefloquine sensitivity in Africa has been suggested by in vitro studies (82,86)  
but clinical mefloquine resistance is rare in Africa. 
Resistance to the antifolates developed more quickly after their introduction. 
Resistance to SP was first reported in the mid 1960s on the Thai-Cambodian border 
(77). Currently, high level resistance is observed in a part of SE Asia, southern China, 
and the Amazon Basin (87,88,89). Lower level of resistance is found on the Pacific 
coast of South America, and in southern Asia and western Oceania (90). In Africa, SP 
resistance was reported in 1980s. Resistance to SP exist throughout Africa in various 
rates (91-97). 
Multidrug resistance of P. falciparum is the resistance to more than two operational 
antimalarial compounds of different chemical classes (85). Areas classified as having 
established multidrug resistance when the drugs of the first two chemical classes 4-
aminoquinolines and antifolates, in addition to a third drug are no longer operationally 
effective. Established multidrug resistance occurs mainly in SE Asia, particularly the 
border regions of Thailand and in the Amazon basin (5).  
In P. vivax SP resistance is more wide spread (98). In P. vivax resistance to SP (99), 
to CQ (100,101) and to primaquine (102) has been documented.  
1.8.2. Mechanisms of resistance to antimalarial drugs 
1.8.2.1. Chloroquine 
Chloroquine attacks the dividing erythrocytic stages of the malaria parasite and 
interferes with parasite hemin (ferriprotoporphyrin IX) detoxification. The site of 
action of CQ as also of other schizonticides such as quinine, mefloquine and 
halofantrine; is within the digestive vacuole (DV) of the blood stage parasite, CQ is 
thought to accumulate to high levels in the DV, where it complexes with heme 
released from hemoglobin digestion and interferes with its polymerization to non 
toxic hemozoin (103,104), resulting in the accumulation of hemin which is toxic for 
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the parasite and damages the enzymes as well as the membrane of its digestive 
vacuole (105).  
Resistance to CQ is related to diminished uptake of the drug. This is achieved by 
prevention of access of CQ to the DV. Yet the biochemical mechanism of CQ 
resistance has remained enigmatic, with different theories. Export of the drug to the 
cytoplasm by means of a protein was suggested, P glycoprotein homologue 1 (pgh1) 
in the vacuole membrane, which is specified by P. falciparum multidrug resistance 
(Pfmdr1) gene in chromosome 5 (106). Another protein produced within the vacuole, 
and specified by the gene cg2 on chromosome 7 was postulated to confer CQ 
resistance (107). Further analysis of the polymorphisms of cg2 suggested that it is not 
the chloroquine resistance effector. Instead an additional transmembrane protein 
located in the DV membrane; encoded by P. falciparum chloroquine resistance 
transporter (Pfcrt) gene which is located in chromosome 7 is postulated to be a CQ 
transporter (108).  
Various hypotheses have been proposed to explain the mechanism of P. falciparum 
resistance to CQ, were reviewed by Jiang and others in 2006 (109). The majority of 
studies have focused on regulation of the DV physiological changes (pH, ion 
exchange and CQ concentration) and CQ efflux. 
Lower pH in the DV of CQ resistant (CQR) parasites was observed to be coupled 
with decreased accumulation of CQ (104,110,111,112). A subsequent study 
confirmed these observations (113). A more acidic pH inside the DV of CQR 
parasites is believed to directly or indirectly increase the aggregation of heme and 
reduce its capacity to bind CQ and therefore reduce toxicity to the parasite.  
Other studies have suggested that Pfcrt may affect chloride ions (Cl-) transport across 
the DV (114,115), thereby influencing the movement of other ions, and eventually 
affecting heme crystallization, CQ binding kinetic and/or CQ partitioning (116). A 
plasmodial sodium-hydrogen ions (Na+-H+) exchanger was suggested in 1997 to be 
responsible for the reduced CQ import in CQR parasites (117), however in 1998 the 
steady state accumulation of CQ inside the digestive vacuole was demonstrated to be 
due to the binding affinity of CQ to heme rather than Na+-H+ exchanger (106), where 
the affinity of saturable CQ heme binding was greatly reduced in CQR parasites 
(105,118,119), although the number of heme binding sites does not differ in 
comparison with CQ sensitive parasites (105,113).  
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Chloroquine efflux across the DV membrane was also proposed as a cause of 
decreased CQ accumulation; the hypothesis was supported by many studies which 
demonstrated an inverse association between CQ efflux and its accumulation (112, 
115,118,120,121,122). Chloroquine efflux was supposed to be an energy dependent 
mechanism, is temporally, indirectly associated with adenosine triphosphate (ATP) 
production after glucose feeding (112,121). Johnson and colleagues (118) have argued 
that CQ efflux is not an energy dependent process but due to a process called “charge-
leak efflux”, an assumption of this model is that Pfcrt can transport drugs directly, as 
predicted by recent bioinformatics analysis studies (123,124). According to this model 
protonated CQ2+ in the digestive vacuole leaks out along its electrochemical gradient 
through Pfcrt, a possible anion channel (118). In CQR parasites carrying Pfcrt 
mutations that lack the positively charged residue such as lysine at codon 76 to 
Threonine or isoleucine or asparagines may allow CQ2+ to leak outside the DV.  
1.8.2.2. Antifolates 
Plasmodium spp. de novo synthesize the folates they need from the simple precursors 
guanosine triphosphate (GTP), P-aminobenzoic acid and glutamate (125), Not all of 
the enzymes involved in folate metabolism have been identified in Plasmodium spp. 
Folate exogenous salvage pathway has been reported (126). Antifolates and sulfa 
drugs target two enzymes in the folate synthesis pathway. Pyrimethamine and 
sufadoxine act synergistically when used in combination. They exert their antimalarial 
activity by binding and inhibiting dihydrofolate reductase (dhfr) and dihydropteroate 
synthase (dhps) enzymes, respectively (127). These two enzymes are involved in 
folate synthesis; disruption of folate synthesis by dhfr and dhps inhibitors leads to 
decreased levels of fully reduced tetrahydrofolate, a necessary cofactor in important 
one carbon transfer reactions in the purine, pyrimidine, and amino acid biosynthetic 
pathways (125). The lower level of tetrahydrofolate results in decreased conversion of 
glycine to serine, reduced methionine synthesis, and lower thymidylate levels with a 
subsequent arrest of deoxyribonucleic acid (DNA) replication (128, 129). 
Resistance to the antifolate drugs is the result of point mutations in the substrate 
binding site of the target enzymes (130,131). In vitro resistance of P. falciparum to 
pyrimethamine and to chlorcycloguanil is due to specific point mutations in P. 
falciparum dihydrofolate reductase (Pfdhfr), which is encoded by a bi-functional gene 
also encoding thymidylate synthase (106,132-135). 
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The Pfdhfr mutations alter the shape of the active cavity where the dhfr inhibitors 
bind the enzyme, resulting in differential binding affinities for different drugs. 
The sulfa drugs inhibit dhps by acting as analogues of p-aminobenzoic acid, a folate 
precursor (127). Point mutations in the P. falciparum dihydropteroate synthetase 
(Pfdhps) gene encoding dhps have been associated with resistance to sulfa drugs and 
sulfones. This gene is bi-functional, and also encoding hydroxymethylpterin 
pyrophosphokinase.  
1.8.3. Molecular basis of antimalarial drugs resistance 
1.8.3.1. Chloroquine, quinine and mefloquine resistance 
Polymorphisms in Pfcrt and Pfmdr1 are the focus of studies on resistance to CQ. In P. 
falciparum CQ resistance is conferred by mutations in the parasite PfCRT (108). One 
mutation, the substitution of threonine for lysine at codon 76 (76T), was perfectly 
associated with in vitro resistance among a set of geographically diverse parasite 
isolates (136). The absolute specificity of the pfcrt 76T to clinical chloroquine 
resistance has been confirmed by several field studies (79). Specific mutations at 
codons 72-76 of Pfcrt define three major haplotypes; CVMNK, CVIET and SVMNT 
(137). The CVMNK haplotype is the worldwide identical wild type, CVIET found in 
most of African/Asian isolates and SVMNT represents the South American/Papua 
New Guinea (PNG) allele (137). The CVIET and SVMNT represent the two major 
CQ resistance selective sweeps in SE Asia and South America, respectively. 
Additional haplotypes were reported in individual samples; SVMIT, RVMNT (138), 
CVMNN (139), SVIET, CVIKT (140), CVIDT and CVTNT (141). SVMNT 
haplotype appeared to be associated with decreased efficacy of amodiaquine (115).  
Mutations in a second transporter (Pfmdr1) have been studied extensively. The 
aspartic acid to tyrosine point mutation in codon 86 (86Y) has been associated with 
CQ resistance in some clinical and in vitro studies (142-146), but not in others (147-
150). Several other pfmdr1 polymorphisms, notably phenylalanine-184 (184F), 
cysteine-1034 (1034C), aspartic acid-1042 (1042D), and tyrosine-246 (1246Y), have 
been implicated as potential contributors to CQ resistance. A parasite transfection 
experiment showed that polymorphisms in the pfmdr1 gene modulate susceptibility to 
chloroquine (151), but their role in determining the in vivo resistance has yet to be 
substantiated (146). Linkage disequilibrium between pfcrt 76T and pfmdr1 86Y has 
been noted in Africa (145,152). 
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Many studies suggested pfmdr1 as the key modulator of quinine and mefloquine 
resistance. In a study of pfmdr1 mutations (86Y, 184F, 1034C, 1042D, 1246Y), 
chloroquine resistant strains were found to have low susceptibility to quinine (81). 
Weak association between pfmdr1 86Y and decreased sensitivity to quinine was 
reported (153). Some studies suggested an inverse association between pfmdr1 86Y 
mutation and resistance to mefloquine (143, 153).  
1.8.3.2. Sulfadoxine-pyrimethamine resistance 
The molecular basis of resistance to SP is the best characterised of all antimalarial 
resistance. Specific mutations in P. falciparum that lead to resistance to both 
sulfadoxine and pyrimethamine have been identified.  
At the present time, point mutations in six codons of Pfdhfr gene are known to be 
associated with pyrimethamine resistance by reducing drug binding capacity in 
resistant P. falciparum strains; include alanine to valine at codon 16 (16V), cysteine 
to arginine at 50 (50R); asparagine to isoleucine at 51(51I), cysteine to arginine at 59 
(59R), serine to asparagine (108N) or to threonine at 108 (108T), and isoleucine to 
leucine at 164 (164L). A serine to asparagine change at codon 108 is the critical 
mutation found in all pyrimethamine resistant isolates (154,155). The 108N is the 
principal mutation causing resistance to pyrimethamine or cycloquanil in Africa and 
in South America (156). The most frequent additive mutations are 51I and 59R (157). 
Asparagine-108 confers pyrimethamine resistance in vitro with only a moderate loss 
of susceptibility to cycloguanil and chlorcycloguanil. 108N in addition to 51I and/or 
59R mutations results in higher levels of pyrimethamine resistance. On the other hand 
a 108T coupled with a 16V, confers resistance to cycloguanil and chlorcycloguanil 
with only a moderate loss of susceptibility to pyrimethamine. Asparagine-108 and 51I 
and/or 59R confers high level resistance to both pyrimethamine and cycloguanil, with 
a more modest effect on susceptibility to chlorcycloguanil when combined with 164L 
(132-136), 164L is absent in Africa and found in areas of high sulfadoxine-
pyrimethamine resistance in Southeast Asia and South America. The mutation 50R is 
found in some areas of South America, and seems to have an effect similar to that of 
the 59R mutation (131,155). The Pfdhfr Triple mutant 108N/51I/59R has been most 
strongly associated with resistance to SP in Africa (156,157).  
Point mutations in five codons of the Pfdhps gene are associated with in vitro 
resistance to sulfadoxine and the other sulfas and sulfones include; serine at codon 
436 to alanine (436A) or pheylalanine (436F); alanine at 437 to glycine (437G); 
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lysine at 540 to glutamic acid (540E); alanine at 581 to glycine (581G); alanine at 613 
to serine (613S) or threonine (613T) (158-160). Glycine-437 and 540E have been 
reported to occur together or singly in various parts of the world (106,161-163). 
Glycine-581 which is rare in Africa, has been observed alone or with 437G in South 
America (131,164). Among these, 437G, followed by 540E, is most strongly 
associated with SP treatment failure in Africa (94,131). 
Both the Pfdhfr and Pfdhps mutations occur in a progressive, step wise fashion, with 
higher levels of in vitro resistance occurring in the presence of multiple mutations 
(131,165). The importance of the mutations in Pfdhfr and Pfdhps genes in conferring 
in vivo resistance to SP has been debated (166,167). An association between the 
prevalence of mutations in both Pfdhfr and Pfdhps genes and SP treatment failure 
rates has been demonstrated (131,165,168,169). Checchi and others demonstrated a 
strong association between SP treatment failure and the presence of the Pfdhps double 
mutant 437G/540E together with Pfdhfr triple mutant (95). 
1.8.3.3. Artemisinin resistance 
Plasmodium falciparum sarco/endoplasmic reticulum calcium-dependent adenosine 
triphosphatase 6 (SERCA-PfATPase6) has recently been identified as target for 
artemisinins. The S769N mutation in SERCA-PfATPase6 was associated with 
decreased in vitro susceptibility to artemether (170). 
1.8.3.4. Atovaquone resistance 
Atovaquone is supposed to target cytochrome b (Cyt B) in the pyrimidine metabolism 
pathway (171). Resistance to atovaquone is associated with point mutations in the Cyt 
B gene, which encodes cytochrome b.  
1.8.4. Molecular markers for antimalarial drugs resistance and outcome of 
treatment 
Associations between clinical treatment outcomes and resistance conferring mutations 
have not been straightforward. This is because treatment outcomes are affected by 
factors other than parasite resistance, including host immune responses (79), 
micronutrient levels (172) and bioavailability and pharmacokinetics (173).  
However, molecular markers are now available that can predict resistance to CQ 
(146) and to SP (174). In the case of CQ, pfcrt 76T provides a single marker for 
chloroquine resistance. 
A strong association between failure to SP and the presence of Pfdhfr/Pfdhps 
quintuple mutant (Pfdhfr 108N, 51I, 59R and Pfdhps 437G, 540E). A high specificity 
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of Pfdhfr 59R and Pfdhps 540E for the presence of Pfdhfr/Pfdhps quintuple mutant 
has been observed by Kublin and others (174), and thus these alleles can be used 
asreliaable markers for SP failure. This hypothesis has been supported by another 
study which reported a strong association between clinical failure to SP treatment and 
the presence of Pfdhfr 59R and Pfdhps 540E (175). 
Markers for resistance to most other antimalarial drugs are lacking because the 
molecular basis of resistance are not yet understood. 
Molecular markers are used as research tools for surveillance for CQ and SP 
resistance. Molecular markers can provide direct evidence of selection for resistant 
parasites by antimalarial drug treatment (94,146,169,176) or prophylaxis (177). 
1.8.5. Evolution of antimalarial drugs resistance 
Many factors contribute to the development and spread of resistance. Gene mutations 
conferring resistance to antimalarial drugs do occur in nature; independently of drug 
effect. Single or multiple point mutations in the plasmodium genome may confer 
resistance to the antimalarials drugs. A number of factors have been identified as 
playing a role in development and spread of drug resistance.  
Characteristics of the antimalarials are important determinants of resistance. This 
argument have been discussed by Mackinnon (178), mutants arising in hosts treated 
with drugs with short half lives or low efficacy will have a fitness only slightly higher 
than the wild type and therefore will only slowly increase in relative frequency. Under 
such condition mutant will take far longer to reach a frequency at which they are 
likely to be transmitted than if hosts were treated with high efficacy drugs or drugs 
with long half lives. In the later situation the drug persists at sub therapeutic 
concentrations in the plasma for extended period of time; after the treatment of the 
primary infection and may exert substantial residual selection on new infections (85) 
especially in areas with intense malaria transmission. Sub therapeutic drug 
concentrations eliminate the most susceptible parasites and leave those that may be 
more fit, to recover and reproduce. Wide spread use of drugs at high intensity serves 
to increase drug pressure and is a determinant for selection of resistant parasite 
populations.  
The nature of the mechanism of resistance can determine the rate at which resistance 
may develop. There are three components to this point; First, the probability of 
establishment of resistance when multiple genes are involved is much reduced 
compared with that for resistance conferred by single genes, since the chance of 
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multiple mutations arising de novo in a single parasite is very small compared to that 
for a single mutation (178). Second the action of the genes involved in resistance; if 
the genes act epistatically; the spread of resistance will be slowed down compared to 
genes act independently (179,180). Third when multiple mutations are required for 
resistance, and they are not at the same locus, recombination, which in malaria occurs 
every transmission cycle, will act to break down (as well as build up) combinations of 
resistance alleles (178).    
The intensity of transmission determines the rate at which drug resistance may 
develop and spread. There are conflicting arguments as to whether resistance spreads 
more rapidly in high transmission or low transmission areas. As endemicity level 
increases the number of parasite genotypes per infection increases (181), thus 
promoting the spread of resistance (180,182). On the other hand recombination 
breakdown which is higher in high transmission areas, would slow the spread of 
resistance (179,180,182,183). Another factor reduces the rate of spread of resistance 
in high transmission areas is that the host population are generally more immune, and 
the drug usage might be lower, thus exposing proportionally fewer parasites to drugs. 
More potent immune responses increase the efficacy of chemotherapy, where a semi 
immune patient might be cured by a drug despite the fact that his parasites are 
partially drug resistant than do non immune hosts (184). Non immune malaria patients 
generate a non specific immune response that is not as effective as the specific 
immunity elicited by repeated infections. Thus, the former situation increases 
manifestation and spread of resistance. 
Vector and environmental factors may influence the proliferation of resistant 
parasites. For example, CQ resistant parasites may be more fit for reproduction in 
certain anopheline mosquitoes than non resistant strains (85). 
The emergence of antimalarial drug resistance is dependent on the occurrence of a 
spontaneous genetic change in a malaria parasite. However for resistance to spread, 
the spontaneous occurrence of a mutation in itself is not sufficient.  
In the absence of the antimalarial, a parasite with the resistant mutation does not have 
a survival advantage and there may even be a survival disadvantage, a so called 
fitness cost to having the mutation (185). Hence antimalarial resistance in malaria 
parasites spreads because it confers a survival advantage in the presence of the 
antimalarial to which it is potentially resistant, where the multiplication of the 
sensitive parasites is inhibited allowing the drug resistant mutants to survive and 
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multiply and therefore increasing the probability of transmission for resistant than for 
sensitive parasites.  
For resistance to be propagated, recrudescence and subsequent transmission of an 
infection that generated resistant malaria parasites de novo are essential (69). As 
resistant infections are more likely to recrudesce, both increased rate of recrudescence 
and slow initial response to treatment increase the likelihood of generating sufficient 
gametocytes densities to transmit compared with drug sensitive infections (98). 
1.8.6. Origin of antimalarial drug resistance genes 
The number of origin of spread of resistance is determined by genotyping of 
molecular markers; single nucleotide polymorphisms and microsatellites situated very 
close to drug resistance genes. Microsatellites are useful markers since they are 
abundant, easily genotyped and have multiple alleles per locus (186). Due to the high 
recombination rate in P. falciparum (187) markers should be positioned as close as 
possible to the resistance genes. 
Two independent origins of CQ resistance was suggested by it's simultaneously 
appearance in SE Asia and South America (188). Chloroquine resistance appeared in 
east Africa 17 years after its occurrence in Asia, followed by systematic progression 
in Africa with little evidence of leapfrogging. (188). 
Four origins of CQ resistance alleles were identified by examining point mutations in 
Pfcrt, including a single origin in SE Asia and Africa, two independent origins in 
South America, and an independent origin in PNG (108). Using microsatellite 
markers these four independent origins were confirmed (137). Two independent 
origins of identical coding changes were demonstrated in PNG and South America in 
2001 (189). Sequencing analysis which is needed to be confirmed by microsatellite 
markers suggested two additional origins of resistant Pfcrt alleles in Cambodia (141), 
and in the Philippines (190). Transfer of the Pfcrt mutant alleles from SE Asia to 
Africa (107,188), and the spread of the same alleles to South America (80) and to the 
Philippines (190) were suggested.  
It was assumed that mutations in Pfdhfr conferring resistance have multiple origins 
(177). Three molecular studies using different microsatellite markers to investigate 
parasites from three different continents demonstrated that this previously suggested 
theory of pyrimethamine resistance evolution is only partially correct (191,192,193). 
All three studies suggested multiple origins of low level resistance, and very limited 
numbers of origins of high level pyrimethamine resistance (with ≥3 mutations). A 
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study comparing parasites from SE Asia carrying two to four mutations with samples 
from South Africa, demonstrated that the triple mutant Pfdhfr alleles spreading 
through Africa have identical or very similar flanking regions to those from SE Asia, 
indicating that these alleles result from import of parasites from SE Asia (194).  
Similarly studies on South American and African parasites suggested; very few 
origins of high level Pfdhps resistance. In South America Pfdhps genes containing a 
single mutation were found on many different microsatellite backgrounds, suggesting 
multiple origins. However, only two different origins of the triple mutant allele were 
demonstrated (191). In Africa, the double mutant Pfdhps allele (A437G/K540E) has a 
single origin and is found on the same genetic background in two studied countries 
(192). In SE Asia, microsatellite diversity is reduced around the Pfdhps locus. 
However, two to three microsatellite haplotypes are found associated with Pfdhps 
alleles, and recombination and mutation muddy the picture (195).  
Duraisingh and others (153) reported limited numbers of origin of Pfmdr alleles 
containing the mutant Tyr-86 associated with CQ resistance, suggested by 
significantly lower levels of microsatellite variation in this allele. Triglia and others 
have investigated the nature and origin of pfmdrl amplicons, they concluded that 
amplification of the pfmdrl gene in P. falciparum has arisen as multiple independent 
events, therefore multiple origins have occurred (196). A study analyzed P. 
falciparum isolates from Thai with high levels of chloroquine and mefloquine 
resistance has suggested two separate origins of pfmdr alleles in the study area (148). 
1.8.7. Assessment of Plasmodium falciparum  susceptibility to antimalrial drugs 
Antimalarial drug susceptibility is commonly assessed by therapeutic response (in 
vivo test). Clinical studies are the gold standard for monitoring antimalarial drug 
efficacy to provide information used by policy makers to establish drug treatment 
policy in endemic areas of Africa. In vivo test is the assessment of clinical and 
parasitological outcomes of treatment over a certain period after the start of treatment, 
to check for the presence and level of the parasite density and taking into account 
clinical factors. 
In vivo response to drugs was originally defined by WHO in terms of parasite 
clearance; sensitive and three degrees of resistance (RI, RII, RIII) (197). It is difficult 
to apply this classification in areas with intense transmission where new infections 
may be mistaken for recrudescences. Therefore, WHO introduced in 1996 a modified 
protocol based on clinical outcome (adequate clinical response, early treatment 
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failure, and late treatment failure) targeting a practical assessment of therapeutic 
responses in areas with intense transmission (198), where parasitemia is common in 
the absence of clinical signs or symptoms (87,90). Then the protocol has also been 
adapted for use in areas of low to moderate endemicity, taking into consideration that 
the objectives of malaria treatment are both parasite clearance and disappearance of 
symptoms (199). However, in vivo testing is costly, laborious and is not ideal for large 
scale epidemiologic surveys.  
Antimalarial drug susceptibility can also be assessed by in vitro drug sensitivity 
assays which measure the sensitivity of P.  falciparum from the inhibition of growth 
or schizont maturation (90,200). In vitro test is impractical due to technical limitations 
and poor correlation with clinical outcomes, largely owing to the role of human host 
immunity (201). However it is useful for validating molecular markers and for 
following changes in resistance patterns.  
Recently, the use of molecular markers has been proposed as an additional tool for the 
early detection of drug resistance in malaria (79). In vitro test results, in particular, do 
not necessarily correspond to in vivo outcomes. Evaluation of molecular markers of 
drug resistance may offer a simple, low cost means of drug efficacy surveillance 
(168). 
1.9. Prevention of resistance by use of combination therapy 
Combination therapy (CT) has been advocated as the standard treatment to prevent 
the spread and development of resistance to antimalarial drugs (202). 
As a response to increasing levels of resistance to antimalarial medicines, WHO 
recommends that all countries experiencing resistance to conventional monotherapies, 
such as chloroquine, amodiaquine or sulfadoxine-pyrimethamine, should use CT, 
preferably those containing artemisinin derivatives (ACTs – artemisinin based 
combination therapies) for falciparum malaria (87,203). 
Antimalarial CT is the simultaneous use of two or more blood schizontocidal drugs 
with independent modes of action and thus unrelated biochemical targets in the 
parasite (5). The concept is based on the potential of two or more simultaneously 
administered schizontocidal drugs with independent modes of action to improve 
therapeutic efficacy and also to delay the development of resistance to the individual 
components of the combination. 
The impact of CT on drug resistance is based on the assumption that drug resistance 
essentially depends on mutation, the probability of a parasite arising that is resistant 
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simultaneously to two drugs with unrelated modes of action is the product of the per 
parasite mutation frequencies multiplied by the total number of parasites exposed to 
drugs (69).  
1.10. Artemisinin based combination therapies (ACTs) 
Artemisinin derivatives are particularly effective in combinations with other 
antimalarials because of their very high killing rates, lack of adverse effects and 
absence of significant resistance (22). 
The primary disadvantage of artemisinin drugs is that they are characterized by a 
short half life. Treatment with artemisinin drugs causes reduction of parasite burden 
below detectable levels without eliminating all parasites; this results in a higher risk 
of recrudescence (67,204). In addition, a fraction of the parasites exposed to the drug 
are thought to become dormant and unsusceptible to further dosing until reactivation 
(205). In order to completely eliminate the parasites and prevent the emergence of 
resistant P. falciparum, combinations with other, longer acting drugs are necessary 
(206,207). Using ART derivatives with other effective drugs ACTs allow a reduction 
in the duration of ART treatment. Several ACTs are currently recommended by WHO 
as the first line antimalarial treatment for P. falciparum malaria, these include the 
combination of artemether with lumefantrine, and the combination of AS with 
amodiaquine, mefloquine or SP. Amodiaquine plus SP may be considered as an 
option where ACTs cannot be made available, provided that efficacy of both is high 
(206). Other ACTs in the pipeline recommended for accelerated development, 
particularly combination of piperaquine-DHA-trimethoprim (ArtecomTM), 
ArtecomTM-primaquine (CV8TM), Lapdap plus AS, Naphthoquine plus DHA and 
pyronaridine plus AS (203). 
1.11. Malaria in Sudan 
1.11.1. The burden of Malaria in Sudan 
In Sudan, malaria is a leading cause of morbidity and mortality resulting in an 
estimated 7.5 million cases and 35,000 deaths annually (208), it accounted for 37.2% 
of all maternal deaths in Sudan at hospital level (209).  
 Malaria is one of the top 10 most common diseases that cause outpatient attendance 
and deaths in Sudan (210). Case fatality rate is high ranging between 0.9 to 6.9%. It is 
increasing every year due to poor case management, low awareness and the 
emergence of drug resistance. 
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1.11.2. Malaria epidemiology in Sudan 
Malaria is endemic throughout the Sudan. Endemicity varies from hypo endemic in 
the North to hyper or holo endemic in the South (Figure 1.3) (210). Considering the 
prevailing epidemiological factors Sudan has been stratified into five malaria strata 
(Figure 1.4); 80% of the population is living in epidemic-prone areas (unstable 
malaria transmission) (210).  
The disease is caused in >90% of cases by P. falciparum though other species are also 
available. In Khartoum it has been shown that about 15% of cases are due to other 
types of Plasmodium (P. ovale =6.2% and P. vivax =8.2%) (211). Anopheles 
arabiensis is the primary vector all over the Sudan but A. gambiae and A. funestes are 
widely found in many areas mainly in the south (210). 
1.11.3. Antimalarial drug resistance in Sudan 
In Sudan, CQ had been used as first line treatment for uncomplicated malaria and SP 
as the second line over a long period of time. Treatment failure of P. falciparum to 
CQ and SP is wide spread in the country. Chloroquine treatment failure has been 
reported firstly in 1978 in Gezira area, central Sudan (212). In 1983 it was 
documented in Khartoum (213), in 1989 and 1990 in eastern Sudan (214,215), and in 
1992 in Gezira (216). Then the situation was worsening where it reached 32.1% in 
Khartoum (219); and more than 75% in eastern Sudan (217,218). In 2001 treatment 
failure to CQ was reported in five sentinel posts (219); and in 2003 in eastern part of 
the country (220). Treatment failure to SP in Sudan has been documented in varying 
levels ranging from 8-69.9% that have been reported from Khartoum (221), eastern 
(222,223,224,225) and southern (226) parts of the country. Four reports have 
indicated treatment failure to quinine in Sudan (218,227,228,229). 
1.11.4. Malaria treatment policy in Sudan 
Wide spread resistance of malaria parasites to commonly available antimalarial drugs 
necessitated the deployment of new antimalarial drug policy. Consistent with WHO 
recommendations; Sudan has changed its national first and second line antimalarial 
treatment from CQ and SP to AS plus SP and artemether plus lumefantrine, 
respectively since June 2004. 
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Figure 1.3: Malaria endemicity level in Sudan, 2001 
Reproduce from the Annual Statistical Report of the Federal 
Ministry of Health (210) 
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Figure 1.4: Sudan Major Malaria Strata, 2001 (212) 
Reproduce from the Annual Statistical Report of the Federal 
Ministry of Health (210) 
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Objectives of the study 
General objectives 
This study aimed at contributing data to help policy makers in planning malaria 
control to adopt drug policies that might delay the spread of antimalarial drug 
resistance.  
The main objective of the study was to examine therapeutic efficacies of two 
antimalarial drug combinations to provide an effective and affordable alternative first 
line treatment for uncomplicated malaria in Sudan. In addition the study aimed at 
examining efficacy of the recently adopted national first line antimalarial treatment 
(AS plus SP) and at providing baseline information on the distribution of SP 
resistance genotypes alleles in P. falciparum in Sudan. 
Specific objectives 
1. To evaluate the safety and efficacy of CQ plus SP and CQ plus DHA for treatment 
of uncomplicated falciparum malaria in Gedaref area. 
2. To assess the prevalence of key mutations in the P. falciparum genes conferring 
resistance to CQ and SP in the same area. 
3. To evaluate the safety and efficacy of the first line antimalarial treatment (AS plus 
SP) for treatment of uncomplicated falciparum malaria in Khartoum. 
4. To assess the frequency of SP resistance marker haplotypes in P. falciparum in 
Khartoum, New Halfa and Kassala. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29
2. Materials and Methods 
2.1. Study sites 
2.1.1. Eastern Sudan 
In eastern Sudan four sites situated in Sudanese savannah were selected (Figure 2.1). 
The climate in the selected sites is characterized by well defined wet and dry periods, 
with a short rainy season from July to September. Malaria is mesoendemic in the four 
areas, characterized by markedly seasonal, unstable transmission, which peaks in 
October following the short rainy season.  
2.1.1.1. Daraweesh and Kajara Villages 
Daraweesh and Kajara, Gedaref State, eastern Sudan. The two villages are about two 
kilometers (km) from each other, and 16 km from the capital of the State (Gedaref 
town), they are inhabited by 550 and 2000 individuals, respectively.  
2.1.1.2. New Halfa 
New Halfa lies 500 km to the east of Khartoum. The area is made up of 250 villages, 
together inhabited by about 400,000 individuals. New Halfa is located in the middle 
of an agricultural scheme with a permanent irrigation system.   
2.1.1.3. Kassala 
Kassala is located in eastern Sudan, about 405 km east of Khartoum, near the border 
with Eriteria; it is surrounded by rounded hills. The population of Kassala is estimated 
to be 149000.  
2.1.2. Haj Yousif (Central Sudan) 
 Haj Yousif, Sharg Alneel locality, Khartoum State (Figure 2.1), situated some 15 km 
northeast center of Khartoum.  Haj Yousif is inhabited by about 500 000 individuals 
according to census, 2001. Malaria is mesoendemic and characterized by seasonal, 
unstable transmission. A small peak of transmission occasionally occurs in December 
and January (230), otherwise general malaria epidemiology in the area is similar to 
that in eastern Sudan. 
2.2. Assessment of efficacy of antimalarial drug combination 
A randomized controlled clinical trial of CQ plus DHA versus CQ plus SP was 
conducted in two neighboring villages, Daraweesh and Kajara, eastern Sudan, in the 
period between October 2002 and January 2003. In addition a clinical trial was carried 
out in Haj Yousif, central Sudan (Alban Jadid hospital), from November 2004 to 
February 2005, to evaluate the recently adopted national first line curative 
antimalarial for uncomplicated falciparum malaria in Sudan (AS plus SP). 
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Figure 2.1: Study areas in Sudan 
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The WHO in vivo protocol for antimalarial drug efficacy (231), with few 
modifications that suit the study sites, was followed in recruitment of patients and in 
evaluating treatment outcome. The modifications included the age of patients and 
parasite density, where patients in all age groups were enrolled because malaria 
transmission in the study areas is density unstable and all inhabitants are susceptible, 
and parasite density was not considered as a criterion for recruitment, since the 
malaria diagnosis is not based on parasite count in these areas, otherwise many cases 
would have been excluded. 
Patients were observed for 28 days using a standardized antimalarial drug efficacy 
record form. 
2.2.1. Study population 
Patients in all age groups were enrolled if they were permanent residents in the study 
sites, proved to have a thick blood film showing asexual P. falciparum monoinfection, 
an elevated axillary temperature (≥37.5°C) or a history of fever during the preceding 
24 hours, and if an informed consent was signed by adult patients or a parent/guardian 
for children. However, pregnant women, patients with severe malnutrition, danger 
signs of severe and complicated malaria defined by WHO guidelines (232), with 
history of hypersensitivity to any of the studied drugs, concomitant febrile infections, 
mixed Plasmodium infections or children can not swallow tablets were excluded. 
Criteria for withdrawal were clinical deterioration necessitating hospital referral and 
patient’s request.  
2.2.2. Clinical examinations and diagnosis 
At enrolment (Day 0) axillary temperature was measured using a digital electronic 
thermometer, then a standardized medical history was obtained and physical 
examination was performed by the study physician. All patients were re-examined on 
each day of follow up in the clinic, including a clinical assessment for adverse 
reactions. 
Thick and thin blood films were made in duplicate; all slides were stained with 3% 
Giemsa stain at pH 7.2 and examined by an expert microscopist according to the 
standard WHO procedure (233). Parasitemia, expressed as the number of asexual 
parasites / µl blood (P/µl) was determined from thick blood smears. The number of 
asexual parasites was counted against 200 white blood cells (WBC) or against 500, if 
the number of parasites was less than 10 per 200 WBC, and then calculated assuming 
8000 WBC per µl as mean WBC. The count was stopped (after completing the last 
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field) if more than 500 parasites have been counted without having reached 200 
WBC. A blood film was considered negative when asexual parasites were not 
detected after the examination of 100 thick film fields. A thin blood smear was also 
examined to confirm parasite species. If P. falciparum gametocytes are seen, a 
gametocyte count is performed against 1000 WBC. Blood smears taken during patient 
follow up were examined in the same manner. 
2.2.3. Samples 
Finger prick blood specimens were collected from all enrolled patients on Day 0, on 
all scheduled follow up days and on any other day if the patient became unwell or 
developed fever. These were used to prepare thick and thin smears and blood spots on 
Whatmann 3 mm filter paper, which were dried and kept at room temperature, each 
sealed in a separate plastic bag until DNA extraction. 
2.2.4. Treatment 
All enrolled patients At Daraweesh and Kajara site (50 patients), were randomly 
assigned to receive either CQ + DHA (25 patients) or CQ + SP (25 patients) 
regimens. While those enrolled at Haj Yousif site (120 patients) were treated with AS 
+ SP.  
Twenty five mg/kg body weight CQ was administered over 3 days (10 mg/kg on day 
0 and day 1, and 5 mg/kg on day 2); SP was administered in a single dose on day 0, 
based on a pyrimethamine level of 1.25 mg/kg of body weight. Dihydroartemisinin 
was given at a dose of 2 mg/kg body weight once in the first day, then 1 mg/kg for 6 
days, and AS was given as 4 mg/kg/day for three days.  
Patients were treated according to the guidelines of the WHO (87,231), all patients 
were treated orally, and a full treatment dose of each combination was adjusted and co 
administered simultaneously. All doses were given under direct supervision. After 
treatment, patients were directly observed for 1 hour, and the full dose was repeated if 
vomiting occurred. Patients who repeatedly vomited their first dose of study 
medication were excluded from the study. Patients received paracetamol (10 
mg/kg/dose) when needed.  
Treatment failure cases were treated with quinine and Artemether + lumefanterene at 
Daraweesh and Kajara site, and in Haj yousif site, respectively. 
2.2.5. Clinical and parasitological follow ups  
Follow up was scheduled for days 1, 2, 3, 7, 14, 21, and 28. Patients were asked to 
return to the clinic any time if became unwell or developed fever. During each visit 
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standardized forms were completed to facilitate the detection of any adverse events, a 
complete physical examination including axillary temperature was performed, thin 
and thick blood smears were examined. Blood spots on filter paper were prepared on 
days 0, 3, 7, 14, 21, and 28 or on any day of recurrent parasitemia after day 3, for 
molecular analysis.  
2.2.6. Treatment outcomes 
2.2.6.1. Primary and secondary end points 
Primary end points were therapeutic response on the basis of parasitological and 
clinical cure by day 28, and safety which was based on the incidence of adverse 
reactions; an adverse reaction was defined as the development of any symptom or 
sign that did not exist before the initiation of treatment, that was not a classic 
symptom or sign of malaria, or as sign or symptom worsening during the course of 
treatment and follow up. Fever clearance time, parasite clearance time, and 
gametocyte carriage on days 7 and 14 were considered as secondary end points. Fever 
and parasite clearance time were defined as the time (days) from initiation of 
treatment to fever and parasite clearance, respectively; fever was judged by 
temperature of 37.5ºC or higher, and by history of fever during the preceding 24 
hours. Gametocyte carriage was the proportion of patients with gametocytes, stratified 
by those with and without gametocytes on day 0. 
2.2.6.2. Clinical and parasitological outcomes 
Clinical and parasitological responses were classified into four groups:  
Early treatment failure (ETF) was defined as the development of one of the following 
during the first three days of follow up: danger signs or severe malaria on day 1, day 
2, or day 3 in the presence of parasitemia; a day 2 parasitemia greater than on day 0 
irrespective of axillary temperature or parasitemia on day 3 with axillary temperature 
≥ 37ºC; parasitemia on Day 3 ≥ 25% of day 0. 
Late clinical failure (LCF) was defined as the development of one of the following 
during the follow up period from day 4 to day 28, without previously meeting any of 
the criteria of ETF: danger signs or severe malaria in the presence of parasitemia; 
unscheduled return of the patient because of clinical deterioration in the presence of 
parasitemia. 
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Late parasitological failure (LPF), defined as the presence of parasitemia on any of 
the scheduled days of return (days 7, 14, 21 or 28) and axillary temperature < 37.5ºC 
without previously meeting any of the criteria of ETF or LCF.  
Adequate clinical and parasitological response (ACPR) was defined as the absence of 
parasitemia on days 7 14, 21 and 28 without developing any of the criteria of early or 
late treatment failure. 
2.2.7. Molecular genotyping 
2.2.7.1. Deoxyribonucleic acid extraction 
Parasite DNA was extracted from the blood spots on filter papers using two different 
methods during different times of this study: 
2.2.7.1.1. Qiagen kit 
Parasite DNA was extracted using commercial kits (QIAmp blood mini kit, Qiagen, 
Hilden, Germany) with minor modifications of the manufacturer's instructions. 
A small piece of the dried blood spot was cut, after cleaning the scissors and scalpels 
with sodium hydroxide. The spot was placed into 1.5 ml micro centrifuge tube and 
incubated for 15 minutes at 85ºC after adding 180 µl of the lysis buffer (ATL). The 
mixture was incubated with 30 µl of proteinase K stock solution at 56ºC for 75 
minutes, and then with 200 µl of the lysis buffer (AL) for 15 minutes at 70ºC, the tube 
was centrifuged after each incubation to remove drops from inside the lid. The sample 
was mixed thoroughly with 200 µl ethanol (96-100%) and the mixture was applied to 
the QIAamp column (in a 2 ml collection tube). QIAamp column was centrifuged two 
times at 8000 round per minute (rpm) for 1 minute and the QIAamp spin column was 
placed in a clean 2 ml collection tube, and the tube containing the filtrate was 
discarded, the second centrifugation was carried out after adding 500 µl of the 
washing buffer (AW1). Five hundred µl of the washing buffer (AW2) was added to 
the QIAamp spin column which was centrifuged again at full speed (14,000 rpm) for 
3 minutes and placed in a clean 1.5 micro centrifuge tube, then the column was 
incubated with 150 µl of the elution buffer (AE) for 3 minutes at room temperature 
and then centrifuged at 8000 rpm for 1 minute. The filtrate was kept at -20ºC until 
used.   
2.2.7.1.2. Chelex  
Extraction of the parasite DNA from the blood spot on filter paper was performed in 
96 well plate format, using the saponin/lysis/chelex extraction method developed by 
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Wooden and others (234) with some modifications described by Pearce and others 
(235). 
Segments of the blood spots were cut using scissors and scalpels which were cleaned 
after each spot by 95% alcohol and flame. The spots were then transferred to 96 
format deep well plates, without using the last column (column 12), 0.8 ml of 0.5% 
saponin in freshly prepared phosphate buffered saline (PBS) was added to each spot, 
and the plate was shaken for 10 minutes at 150 rpm and incubated overnight at room 
temperature. The spot was then washed twice in 0.8 ml of PBS, using a 96 well sucker 
to remove the supernatant, the sucker was cleaned after each wash with 5 M 
hydrochloric acid (HCL) followed by water in deep well format plates. The plate was 
then boiled for 8 minutes, after adding 100 µl of PCR quality water and 50 µl of 20% 
Chelex suspension in distilled water (pH 9.5) to each spot. The plate was cooled for 
10 minutes at room temperature and spinned down at maximum speed for 5 minutes. 
A part of the supernatant was transferred to a new 96 well plate, leaving chelex in the 
original deep well plate, both plates were then stored in -20ºC for subsequent analysis.  
2.2.7.2. Typing of merozoite surface protein 1 and 2 genes 
To distinguish recrudescence from new infections molecular genotyping was 
performed using paired samples from all patients experiencing late clinical or 
parasitologic failure on follow up days 4–28. 
Polymorphic repetitive regions of two P. falciparum antigen loci, block 2 of MSP-1 
and block 3 of MSP-2 were genotyped for allelic variation using nested PCR assays as 
described previously after minor modifications (236).  
Outer PCR assays using primers corresponded to conserved sequences flanking these 
regions, followed by five separate nested PCR reactions were carried out to amplify 
the MAD20, Kl and RO33 allelic families of MSP-l, the FC27 and the IC1 allelic 
families of MSP-2, outer PCR product and allelic specific oligonucleotide primer pair 
were used in each nested PCR reaction, the sequences of the primers for both outer 
and nested reactions are presented in Table 2.1.   
All outer and nested PCR reactions, took place in a total volume of 20 µl containing a 
final concentration of 0.125 µM each primer, 125 µM each of the 4 deoxynucleoside 
triphosphate (dNTPs); (dATP, dCTP, dGTP and dTTP) and 0.4 units of HotStart Taq 
polymerase. 
To initiate all the outer reactions 1 µl of the extracted DNA was used, and 1 µl of the 
outer PCR product was used to initiate each of the 5 separate nested reactions. 
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Genomic DNA from laboratory P. falciparum clones 3D7, HB3, and RO33 were used 
as controls for MAD20, K1 and RO33 MSP-l families respectively, and HB3 and 3D7 
for FC27 and ICI MSP-2 families respectively.  
All the outer and nested reactions for MSP-l and MSP-2 were performed with an 
initial denaturation for 2 minutes (min) at 94°C, followed by 30 amplification cycles 
with annealing at 58°C and extension at 65°C for 2 min for the outer reaction and 1 
min for the nested reaction. The last extension step was carried out for 5 min. 
Another method was used to perform the outer and nested PCR reactions at the 
beginning of this study using 26 µl outer PCR amplification mixture contained a final 
concentration of 0.16 µM of each primer (MWG Biotech, UK), 125 µM each dNTPs 
(Invitrogen, UK), 1 unit of Taq polymerase (Amersham, UK), 0.1 mg/ml gelatine. A 
50 µl nested reaction mixture was prepared as described for the outer reaction with 
increasing the final concentration of each dNTPs to 175µM. 
Two µl of extracted DNA were used as a template in the outer reactions, and 1 µl of 
the product generated in the first reaction was used in each of the nested reactions. 
Outer reactions for MSP-l and MSP-2 were performed with an initial denaturation for 
5 min at 94°C, followed by annealing at 58°C for 2 min, and extension at 72°C for 2 
min. The last extension was carried out for 10 min. The same cycling conditions were 
applied to perform the nested reactions after adjusting the annealing temperature to 
63°C and the last extension to 5 min. 
Thirty five cycles were performed for the outer reactions and 30 cycles for all nested 
reactions.   
2.2.7.3. Visualization of the amplification product 
Nested PCR products were analyzed by electrophoresis using 1.5% GTG Nusieve 
agarose gels or metaphorous gels (Cambrex, Germany), stained with ethidium 
bromide in TBE buffer (100 mM Tris, 100 mM boric acid and 5 mM 
ethylenediaminetetraacetic acid "EDTA"). A mixture of 8 µl of the amplified DNA 
and 2 µl of loading buffer were loaded on the gels; paired samples from the same 
patient were run on adjacent lanes. DNA molecular weight marker; 50 base pair (bp) 
ladder, XIV (Roche, UK) was run in the first and last lanes. The gel was run in TBE 
at 60 voltages for about 45 to 60 min. DNA was visualized by ultraviolet 
transillumination and the gel was photographed. 
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2.2.7.4. Assessment of treatment outcomes  
Treatment outcomes were assessed by comparing genotyping patterns on the day of 
treatment failure with genotyping patterns on the day of enrolment. Each band 
assigned a molecular weight within the expected size of MSP-l and MSP-2 genes, was 
considered an individual strain.  
If all strains present on the day of failure were present on the day of enrolment the 
treatment failure was classified as true recrudescence. However it is classified as a 
new infection if none of the strains present on the day of failure were present on the 
day of enrolment. If the sample on the day of failure contained any of the strains 
present on the day of enrolment and any strain not present on the day of enrolment the 
treatment failure was considered as mixed.  
2.3. Detection of polymorphisms in sulfadoxine-pyrimethamine and chloroquine 
resistance marker genes 
Studies to detect polymorphisms in the molecular markers of P. falciparum resistance 
to SP, Pfdhfr and Pfdhps genes and to CQ, pfmdr1 and pfcrt genes were conducted in 
different areas. 
2.3.1. Parasite deoxyribonucleic acid 
Pretreatment parasite isolates used in these studies were obtained from uncomplicated 
falciparum malaria patients participated in the two clinical trials in Gedaref and Haj 
Yousif areas, and in other two ongoing malaria treatment studies in New Halfa and 
Kassala, eastern Sudan. Parasite DNA was extracted as described in section 2.2.7.1. 
Samples obtained from in New Halfa at Alhara Aloula Health Centre and from in 
Kassala at Alsawagi Alganoubia Health Centre during the period September to 
November 2005.  
Fifty parasite isolates were obtained from Daraweesh and Kajara site, 108 from Haj 
Yousif, 79 from New Halfa and 49 from Kassala.  
2.3.2. Methods 
During the course of this study two different methods were used to detect 
polymorphisms in the drug resistance marker genes (Pfdhfr and Pfdhps).  
(a) Polymerase chain reaction followed by restriction fragment length polymorphism 
(RFLP) assay, and (b) PCR followed by enzyme linked immunosorbent assay 
(ELISA). Polymorphisms in Pfcrt and Pfmdr1 genes were detected using PCR-RFLP 
method. 
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2.3.2.1. Polymerase chain reaction and restriction fragment length 
polymorphism 
Polymorphisms in Pfdhfr, Pfdhps, Pfcrt and Pfmdr1 were detected using PCR assays; 
followed by RFLP analysis. DNA samples of known alleles of the above genes were 
used as positive controls. 
Single base changes in the PCR products were detected by RFLP analysis. Restriction 
digestion was carried out overnight, 5 µl of the PCR product was incubated with 
mutation specific restriction enzymes in a 15 µl final concentration at the optimum 
temperature according to supplier protocol (New England Biolab, UK). Digestion 
products were separated by electrophoresis in an ethidium bromide stained 1.5-3% 
agarose (SeakemTM) gel (Cambrex), 100 bp marker (New England Biolab, UK) were 
used to size the bands. Mixed alleles (both wild type and mutant alleles present) were 
considered mutant. 
2.3.2.1.1. Plasmodium falciparum dihydrofolate reductase and dihydropteroate 
synthetase genes 
 To detect polymorphisms in Pfdhfr and Pfdhps PCR-RFLP method was carried out as 
described before (237,238). 
A nested PCR method was used to amplify the regions surrounding the 
polymorphisms in the Pfdhfr gene at codons 16, 51, 59, 108 and 164, and those at 
codons 436, 437, 540, 581, and 613 in the Pfdhps. Primer sequences are presented in 
Table 2.2. 
In each outer PCR assay 2 µl DNA were amplified in a 50 µl reaction mixture 
containing 0.25 µM of each primer (MWG Biotech, Germany), 200 µM of each 
dNTPs (Invitrogen, UK), 1 unit Taq polymerase (Amersham, UK). 
For Pfdhfr, amplification was performed for 45 cycles with denaturation at 94ºC for 1 
min, annealing at 45ºC, extension at 72ºC; each for 1.5 min. An Initial denaturation 
was at 94ºC for 3 min and a final extension was for 10 min at 72ºC. For Pfdhps 
cycling conditions as for Pfdhfr but the first five annealing and extension steps were 
carried out for 2 and 1 min, respectively. 
Second round PCR was carried out in volumes of 50 µl, prepared as described for the 
first round PCR; to amplify 2µl of the amplified DNA. Thirty five cycles were used, 
cycling conditions were as the first round PCR, but each of the annealing and 
extension steps were carried out for 1 min.  
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A 648 bp portion of the Pfdhfr gene amplified by using the primers M1 and M5 in the 
first round PCR was used as a template for two separate second round PCR using F-
M4 and M3-F/ primer pairs. Similarly K-K/, K/-J and L-L/ primer pairs were used to 
carry out three separate second round PCR using as a template 710 bp portion of the 
Pfdhps gene which was amplified in the first round PCR by using R2 and R/ primers.  
For the Pfdhfr gene, the PCR product (522 bp) generated in the amplification with 
M3-F/ primer pair was used to discriminate between the three alternative forms of 
codon 108 by digestion with restriction enzymes AluI, BsrI and BstNI to detect serine, 
asparagine and threonine respectively. In addition the restriction enzyme NlaIII, 
Tsp5091 and DraI were used to discriminate between the polymorphic variants of 
codon 16 (alanine and valine), codon 51 (asparagine and isoleucine) and codon 164 
(isoleucine and leucine), respectively. To examine codon 59 the 329 bp PCR product 
of the primers M4 and F was digested by XmnI restriction enzyme to differentiate 
between cysteine and arginine variants. 
For the Pfdhps gene, to distinguish between serine and alanine at codon 436; the 438 
bp PCR product given by the primers K and K/ was digested by Mn1I. The PCR 
product of the primer pair K/-J (436 bp) was digested by HindIII to identify the 436-
phenylalanine mutation, in the same way PCR product was digested by MwoI to 
distinguish between alanine and glycine at codon 437, and by FokI to distinguish 
between lysine and glutamic acid at codon 540. The 161 bp PCR product produced by 
the primer pair L-L/ was digested by BstUI to discriminate between 581-A and 581-G, 
the same PCR product was digested by MwoI to identify 613-A, and by AgeI to 
differentiate between 613-S and 613-T. 
2.3.2.1.2. Plasmodium falciparum chloroquine resistance transporter and 
multidrug resistance genes 
Polymerase chain reaction followed by RFLP analysis was used to detect the two 
alleles of Pfcrt gene at codon 76 (146) and of Pfmdr1 at codon 86 (144,239). Primer 
sequences are shown in Table 2.3.  
A primary round of PCR using flanking primers TCRP1 and TCRP2 and 2 µl DNA to 
amplify a 537 bp region around the mutation K76T was performed, in the second 
round, TCRD1 and TCRD2 amplified a 134 bp portion of the Pfcrt gene. For both 
Primary and secondary PCR a reaction volume of 50 µl contained a final 
concentration of 1 µM of each primer, 200 µM of  each dNTPs, 2.5 mM MgCl2 and 
1.5 units of Taq polymerase was used. The first and second reactions conditions 
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consisted of an initial denaturation step of 5 min at 94°C followed by amplification 
cycles each consisted of denaturation for 30 seconds at 94°C, and annealing for 30 
seconds at 56°C and 48°C for the first and second reaction respectively, extension for 
1 min at 60°C and final extension at 60°C for 3 min. Forty five cycles were performed 
for the first reaction and 30 cycles for the second reaction.  
Restriction enzyme Apo1 which indicate the wild type at codon 76 (76K) was used to 
digest the 134 bp PCR product. 
A 330 bp DNA fragment of the Pfmdr1 gene was amplified under the following 
conditions: 3 µl of DNA template, 0.5 µM of the primers Pfmdr1–1 and Pfmdr1–2, 
200 µM dNTP and one unit of HotStart Taq polymerase in a 50 µl reaction. 
Denaturation at 95ºC was performed for 16 min, followed by 45 cycles of 
denaturation at 94ºC for 45 seconds, annealing at 49ºC for 1 min, and extension at 
72ºC for another min, with final extension at 72ºC for 10 min. 
To identify the mutant type tyrosine (86Y) the amplification product was digested by 
AflIII. ApoI enzyme was used to confirmed mixed alleles.  
2.3.2.2. Polymerase chain reaction and enzyme linked immunosorbent assay 
Single nucleotide polymorphisms in the Pfdhfr and Pfdhps genes were detected using 
PCR and ELISA as described by Alifrangis and others in 2003 (240).  
2.3.2.2.1. Amplification of Plasmodium falciparum dihydrofolate reductase and 
dihydropteroate synthetase genes  
Fragments of Pfdhfr (594 bp) and Pfdhps (711 bp) which contain the coding sequence 
where known sites of sequence polymorphism are found, namely codons 50, 51, 59, 
108, 164 of the Pfdhfr gene, and codons 436, 437, 540, 581, 613 of the Pfdhps gene, 
were amplified in a 96 well plate format by independent nested PCR (236,241). PCR 
primers are indicated in Table 2.4, M9 and R/ primers for Pfdhfr and Pfdhps nested 
PCR were biotinylated at the 5´ end by the supplier (MWG, Biotech, Riskov, 
Denmark). 
The 20 µl of each of Pfdhfr, Pfdhps outer PCR mixture contained 0.25 µM final 
concentration of either set of the primers M1/M7 or N1/N2 of Pfdhfr and Pfdhps 
respectively, 0.3 mM of each dNTPs and 1 unit HotStart Taq polymerase (Qiagen, 
Albertslund, Denmark), 1 µl of the template DNA was added to the outer reaction 
mixture. A standardized control panel of P. falciparum isolates which represent 
almost all known SNPs of Pfdhfr and Pfdhps were added in column 12.  For nested 
PCR 1 µl of each the Pfdhfr and Pfdhps outer PCR product was added to 25 µl PCR 
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reaction mixture which was the same as the outer PCR mixture, with decreasing the 
concentration of each dNTP to 0.2 mM and using primer set M3b/M9 (Pfdhfr) and 
R2/R/ (Pfdhps). 
Each of Pfdhfr and Pfdhps outer PCR was carried out with an initial incubation for 2 
min at 94ºC, followed by a total of 40 cycles with denaturation at 94ºC for 1 min, 
annealing at 52ºC for 2 min and elongation at 65ºC for 1 min and final extension for 
10 min at 65ºC. Nested PCR cycling conditions for Pfdhfr were 94ºC for 2 min 
followed by 5 cycles (94ºC/1 min, 44ºC/2 min and 65ºC/1 min followed by 35 cycles 
(94ºC/1 min, 44ºC/1 min and 65ºC/1 min. However Pfdhps nested PCR was 
performed with starting incubation in 94ºC for 3 min and 40 cycles (94ºC/1 min, 
51ºC/2 min and 65ºC/1 min) and extension at 65ºC for 10 min.   
2.3.2.2.2. Sequence specific oligonucleotide probes - enzyme linked 
immunosorbent assay  
The ELISA plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with 
streptavidin in PBS (1 µg/ml), covered, and left overnight at 4°C.  
The nested PCR products were diluted 1:10 in water in a 96 well PCR plate, 
denatured at 95°C for 5 min, and immediately cooled to 4°C until use. 
To enable simultaneous probing with sequence specific oligonucleotide probes 
(SSOPs) targeting the full panel of Pfdhfr and Pfdhps SNP haplotypes, replicate of the 
coated ELISA plates were washed three times in washing buffer (PBS containing 
0.05% Tween 20). The plates were then incubated for one hour at room temperature; 
with 100 µl of cold washing buffer and 2 µl of the diluted PCR products in each well 
and then washed three times in washing buffer.  
The 3´end digoxigenin conjugated SSOPs (MWG Biotech, Denmark), (Table 2.5) 
were diluted in tetramethyl ammonium chloride (TMAC; Sigma Aldrich, Germany) 
solution (3 M TMAC, 50 mM Tris, pH 8.0, 0.1% sodium dodecyl sulfate, 2 mM 
EDTA, pH 8.0) to 20 nM, 4 nM final concentration of 50/51 CN/CI and each of the 
other used SSOPs respectively, the mixtures were heated to 53°C, and 100 µl was 
added to each well. 
The plates were then incubated in a hybridization oven (AH Diagnostics, Aarhus, 
Denmark) at 53°C on a shaking device for one hour, and washed three times in 
washing buffer. This was followed by two rounds of a stringent washing and 
incubation for 10 minutes per round in TMAC solution at the temperatures indicated 
in Table 2.5. The plates were then washed three times in washing buffer to remove 
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TMAC, and peroxidase-conjugated anti-digoxigenin antibody in dilution buffer 
(1:1,000) (Roche Diagnostics, Mannheim, Germany) was added to each well and 
incubated for one hour at room temperature. After washing the plates three times in 
washing buffer, 100 µl an o-phenylenediamine solution of 1.5 mg/ml of 1,2-
phenyldiamine dihydrochloride (Dako, Glostrup, Denmark) dissolved in water 
containing 0.015% H2O2 was added to each well. The reaction was stopped after 30 
minutes by adding 1.25 M H2SO4 and the optical density (OD) was measured in an 
ELISA reader at 492 nm.  
2.3.2.2.3. Scoring of enzyme linked immunosorbent assay results 
To score the ELISA results, a simple analysis test for the positive and negative control 
samples was performed to set a threshold for positivity for each SNP test. 
For each SNP analysis parasite samples were categories into single genotype when 
only one SNP was present at OD value above the threshold of positivity. Mixed with a 
dominant SNP genotype single genotype was considered when the OD value of the 
weakly reacting SSOP was less than half the OD value of the strongly reacting SSOP. 
The infections was categorized as mixed with no dominant genotype, if the OD value 
of the weakly reacting SSOP was higher than half the OD value of the strongly 
reacting SSOP. 
For samples that contained infections categorized as single or mixed with a dominant 
SNP type, at all analyzed codons, results were combined to construct haplotypes. 
2.4. Statistical Analysis 
Statistical analysis was performed using Statistical package for Social Science (SPSS) 
software version 11. Qualitative data were compared using Pearson’s chi-square or 
Fisher’s exact test. Mean values of normally distributed continuous data were 
compared using Student’s t test and one way analysis of variance. Data not 
conforming to a normal distribution were compared by the Mann-Whitney U test or 
the Kruskal-Wallis one-way analysis of variance on ranks. Dependence of 
quantitative values was controlled by correlation. A P value < 0.05 was considered 
significant. 
2.5. Ethical considerations 
The protocols of the studies were reviewed and approved by the Ethics committee, 
Ministry of Health, Khartoum, Sudan or by the Ethical Committee, Faculty of 
Medicine, University of Khartoum. Informed consent was obtained before enrolment 
from each patient or legal guardians of minors. The recruited subjects were informed 
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that they were free to withdraw their consent at any time during the study. Treatment 
was provided free of charge. A medical team was available in the study sites on daily 
basis during the study period, and the patients were under close medical supervision. 
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Table 2.1: Polymerase chain reaction primer sequences used for genotyping of 
merozoite surface protein -1 and 2 (MSP-1 and MSP-2) 
 
Gene Primer Sequence 
M1 – OF 5´-CTAGAAGCTTTAGAAGATGCAGTATTG-3´ 
M1 – OR 5´-CTTAAATAGTATTCTAATTCAAGTGGATCA-3´ 
M1 – KF 5´-AAATGAAGAAGAAATTACTACAAAAGGTGC-3´ 
M1 - KR 5´-GCTTGCATCAGCTGGAGGGCTTGCACCAGA-3´ 
M1 – MF 5´-AAATGAAGGAACAAGTGGAACAGCTGTTAC-3´ 
M1 – MR 5´-ATCTGAAGGATTTGTACGTCTTGAATTACC-3´ 
M1 – RF 5´-TAAAGGATGGAGCAAATACTCAAGTTGTTG-3´ 
MSP-I 
M1 - RR 5´-CATCTGAAGGATTTGCAGCACCTGGAGATC-3´ 
   
M2 – OF 5´-ATGAAGGTAATTAAAACATTGTCTATTATA-3´ 
M2 – OR 5´-CTTTGTTACCATCGGTACATTCTT-3´ 
M2 – FCF 5´-AATACTAAGAGTGTAGGTGCARATGCTCCA-3´ 
M2 – FCR 5´-TTTTATTTGGTGCATTGCCAGAACTTGAAC-3´ 
M2 – ICF 5´-AGAAGTATGGCAGAAAGTAAKCCTYCTACT-3´ 
MSP-2 
M2 - ICR 5´-GATTGTAATTCGGGGGATTCAGTTTGTTCG-3´ 
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Table 2.2: Sequences of the primers used for the detection of polymorphisms in 
the Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and 
dihydropteroate synthetase (Pfdhps) genes using polymerase chain reaction – 
restriction fragment length polymorphism (PCR-RFLP) method  
 
Gene Primer  
M1 5´-TTTATGATGGAACAAGTCTGC-3´ 
M5 5´-AGTATATACATCGCTAACAGA-3´ 
M3 5´-TTTATGATGGAACAAGTCTGCGACGTT-3´ 
F/ 5´-AAATTCTTGATAAACAACGGAACCTttTA-3´ 
F 5´-GAAATGTAATTCCCTAGATATGGAATATT-3´ 
Pfdhfr  
 
 
M4 5´-TTAATTTCCCAAGTAAAACTATTAGAGCTTC-3´ 
   
R2 5´-AACCTAAACGTGCTGTTCAA-3´ 
R/ 5´-AATTGTGTGATTTGTCCACAA-3´ 
K 5´-TGCTAGTGTTATAGATATAGGATGAGCATC-3´ 
K/ 5´-CTATAACGAGGTATTGCATTTAATGCAAGAA-3´ 
J 5´-TGCTAGTGTTATAGATATAGGTGGAGAAAGC-3´ 
L 5´-ATAGGATACTATTTGATATTGGACCAGGATTCG-3´ 
Pfdhps  
 
 
 
L/ 5´-TATTACAACATTTTGATCATTCGCGCAACCGG-3´ 
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Table 2.3: Primer sequences used for the amplification of Plasmodium falciparum 
chloroquine resistance transporter (Pfcrt) and multidrug resistance (Pfmdr1) 
genes  
 
Primer Sequence 
TCRP1 5´-CCG TTA ATA ATA AAT ACA CGC AG-3´ 
TCRP2 5´-CGG ATG TTA CAA AAC TAT AGT TAC C-3´ 
TCRD1 5´-TGT GCT CAT GTG TTT AAA CTT-3´ 
TCRD2 5´-CAA AAC TAT AGT TAC CAA TTT TG-3´ 
pfmdr1–1 5´-AGA TGG TAA CCT CAG TAT CA-3´ 
pfmdr1–2 5´-TTA CAT CCA TAC AAT AAC TTG-3´ 
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Table 2.4: Primer sequences used for the detection of polymorphisms in 
Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate 
synthetase (Pfdhps) genes using polymerase chain reaction and enzyme linked 
immunosorbent assay  
 
 
Gene Primer  
M1 5´-TTTATGATGGAACAAGTCTGC-3´ 
M7 5´-CTAGTATATACATCGCTAACA-3´ 
M3b 5´-TGATGGAACAAGTCTGCGACGTT-3´ 
Pfdhfr  
  
 
M9 5´-CTGGAAAAAATACATCACATTCATATG-3´ 
   
N1 5´-GATTCTTTTTCAGATGGAGG-3´ 
N2 5´-TTCCTCATGTAATTCATCTGA-3´ 
R2 5´-AACCTAAACGTGCTGTTCAA-3´ 
Pfdhps  
 
R 5´-AATTGTGTGATTTGTCCACAA-3´ 
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Table 2.5: Sequences of the specific sequence oligonucleotide probes (SSOP) used 
for the Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and 
dihydropteroate synthetase (Pfdhps) polymerase chain reaction and enzyme 
linked immunosorbent assay  
 
SSOP 
(temperature) 
SSOP sequence Isolate 
Pfdhfr  
50/51CN  
50/51CI  
(58ºC) 
 
TGG AAA TGT AAT TCC CTA  
TGG AAA TGT ATT TCC CTA  
 
3D7, FCR3, K1, HB3 
DD2, 7G8 
59C  
59R  
(60ºC) 
AAT ATT TTT GTG CAG TTA  
AAT ATT TTC GTG CAG TTA  
3D7, FCR3, 7G8, HB3 
DD2, K1 
108S  
108N  
108T  
(62ºC) 
A AGA ACA AGC TGG GAA AG  
A AGA ACA AAC TGG GAA AG  
A AGA ACA ACC TGG GAA AG  
3D7 
DD2, K1, HB3, 7G8 
FCR3 
164I  
164L 
(62ºC) 
GT TTT ATT ATA GGA GGT T 
GT TTT ATT TTA GGA GGT T  
3D7, FCR3, DD2, 7G8, K1, HB3 
Patient's isolates (TN518, TN542) 
Pfdhps   
436/437AA  
436/437AG  
436/437SA  
436/437SG  
436/437FG 
(60ºC) 
GAA TCC GCT GCT CCT TTT  
GAA TCC GCT GGT CCT TTT  
GAA TCC TCT GCT CCT TTT  
GAA TCC TCT GGT CCT TTT  
GAA TCC TTT GGT CCT TTT  
Patient's isolate (AA J.A) 
Patient's isolate (TN518) 
FCR3, HB3 
3D7, 7G8, K1 
DD2 
540K  
540E  
(60ºC) 
ACA ATG GAT AAA CTA ACA  
ACA ATG GAT GAA CTA ACA  
3D7, FCR3, DD2, K1, 7G8, Hb3 
Patient's isolates (TN518, TN542) 
581A 
581G 
(62ºC) 
A GGA TTT GCG AAG AAA CA  
A GGA TTT GGG AAG AAA CA  
3D7, FCR3, DD2, 7G8, HB3 
K1 
613A 
613S 
(62ºC) 
GA TTT ATT GCC CAT TGC  
GA TTT ATT TCC CAT TGC  
3D7, FCR3, 7G8, K1, HB3  
DD2 
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3. Results 
3.1. Efficacy of chloroquine plus sulfadoxine-pyrimethamine and chloroquine 
plus dihydroartemisinin 
3.1.1. Treatment outcomes 
A total of 50 patients were included in the study, these were most of the patients who 
had developed uncomplicated P. falciparum malaria during the malaria season in 
Daraweesh and Kajara villages. Baseline characteristics of the patients are shown in 
Table 3.1. 
Twenty five patients were treated with CQ+DHA, and 25 were treated with CQ+SP. 
Forty six patients completed the 28 days follow up, and had a treatment outcome that 
could be evaluated, four patients withdrew from the study after completing the 
treatment doses (three patients refused to continue and one patient had left the 
village).  
 
Table 3.1: Baseline characteristics of uncomplicated falciparum malaria patients 
treated with chloroquine plus dihydroartemisinin (CQ+DHA) and with 
chloroquine plus sulfadoxine-pyrimethamine (CQ+SP) in Daraweesh and Kajara 
villages, eastern Sudan  
 
Characteristic CQ+DHA CQ+SP 
Median ± 25th; 75th age in years  12 ± 8; 20.5 18 ± 9; 22  
Children: adults (%) 56:44 44:56 
Male: female (%) 56:44 56:44 
History of previous antimalarial (%) 92 88 
Mean ± SE body weight (kg) 33.6 ± 3.01 (45) 34.64 ± 2.86  
Mean ± SE axillary temperature (ºC) 37.87 ± 0.18 (3.1)  37.41 ± 0.17  
Median ± 25th; 75th parasitemia (/µl) 8760 ± 1380; 16000 14800 ± 2880; 20000 
Proportion with gametocytes (%) 28 12.5 
 
3.1.1.1. Primary outcomes 
All patients tolerated the two regimens well, no adverse reactions were reported. In 
approximately one third of the patients treatment failed with no significant difference 
in cure rates between the two treatment groups; (CQ + DHA, 68.2% (15/22); CQ + 
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SP, 62.5% (15/24), P= 0.46. Early treatment failure (ETF) was not observed, LPF 
occurred slightly more frequently than LCF in both groups (Table 3.2). Of the 16 
patients experiencing treatment failure, recrudescence was observed in 15 patients 
(93.8%); and treatment failure was due to reinfection in one patient. 
 
Table 3.2: Treatment outcome of the two studied antimalarial drug combinations 
in Daraweesh and Kajara villages, eastern Sudan 
 
Treatment outcome 
Percentage  (Number) 
Total treatment failure 
Antimalarial drug 
combination
ACPR  LCF LPF Total 
Crude PCR adjustment
CQ plus DHA 68.2 
(15) 
13.6 
(3) 
18.2 
(4) 
100 
(22) 
31.8 
(7) 
31.8 
(7) 
CQ plus SP 62.5 
(15) 
12.5 
(3) 
25 
(6) 
100 
(24) 
37.5 
(9) 
33.3 
(8) 
Total 30 6 10 46 16 15 
 
• CQ = Chloroquine 
• DHA = Dihydroartemisinin 
• SP = Sulphadoxine-pyrimethamine 
• ACPR = Adequate clinical and parasitological response 
• LCF = Late clinical failure 
• LPF = Late parasitological failure 
 
3.1.1.2. Secondary outcomes 
Fever clearance time (median ± 25th; 75th) was 1 day ± 1; 1.5 in both groups; range 
was 2 and 6 in CQ+DHA and CQ+SP regimen, respectively.  
Asexual parasitemia was cleared more rapidly in patients receiving CQ+DHA 
compared to CQ+SP (median parasite clearance time ± 25th; 75th) were 1 ± 1; 2 and 2 
± 1; 2, respectively. On day 1 of treatment prevalence of asexual parasitemia, was 
reduced to a larger extent in the CQ+DHA group (72%) compared to CQ+SP (28%) 
group. By day 3, 1/23 (4.3%) and 2/24 (8.3%) patients were parasitemic among the 
CQ+DHA and CQ+SP group, respectively (Figure 3.1). Among patients treated with 
CQ+DHA; day 0 median parasite density was 8,760 P/µl (range = 25920), it was 200 
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P/µl (range = 10200) and 360 (range = 680) on day 1 and 2, respectively.  Among 
those treated with CQ+SP; median parasite density was 14,800 P/µl blood (range = 
103440), 2040 P/µl blood (range = 17320) and 760 P/µl (range = 240) on day 0, day 1 
and day 2.  
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Figure 3.1: Proportion of parasitemic patients following treatment with 
chloroquine plus dihydroartemisinin (CQ+DHA) and with chloroquine plus 
sulfadoxine-pyrimethamine (CQ+SP) in Daraweesh and Kajara villages, eastern 
Sudan  
 
In CQ+DHA regimen; at baseline the proportion of patients with gametocytes was 
28% (7 of 25). Of these, 5 (71.4%) and 3 (42.9%) were still gametocytemic on day 7 
and 14, respectively, no gametocytes were detected on day 28. While in CQ+SP 
regimen; the proportion at baseline was 12% (3 of 25). All of these were still 
gametocytemic on day 7 and 14, on day 28 two of them were gametocytemic (Figure 
3.2). Among the patients who had no gametocytes at baseline, in CQ+DHA regimen; 
two patients were gametocytemic on day 7. While in CQ+SP regimen; 9 and 2 
patients were gametocytemic on day 7 and 14, respectively.
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Figure 3.2: Proportion of gametocytes carriers among patients treated with 
chloroquine plus dihydroartemisinin (CQ+DHA) and with chloroquine plus 
sulfadoxine-pyrimethamine (CQ+SP) in Daraweesh and Kajara villages, eastern 
Sudan  
 
3.1.2. Polymorphisms in Plasmodium falciparum dihydrofolate reductase, 
dihydropteroate synthetase, chloroquine resistance transporter and multidrug 
resistance genes in Daraweesh and Kajara Villages 
No mutations were detected in Pfdhfr at codons 16, 59, or 164 (Table 3.3). For the 
other two codons, 51 and 108, the percentage of mutations was 84% (42/50) each, and 
there were no mixed wild/mutant infections (Figure 3.3). There was strong linkage 
between the two SNPs (P ≤ 0.001), where all isolates had mutation at codon 51 also 
had mutation at codon 108, and vise versa. 
Similarly, SNPs in five codons of Pfdhps were investigated. Codons 436, 437, and 
613 all contain wild type (Table 3.3). High frequency of mixed wild/ mutant alleles 
for Pfdhps K540E was seen in 80% (39/49) of the examined parasites. Mutant Pfdhps 
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581G allele occurred in 20% of the examined isolates. No association between pfdhps 
540E and 581G (P = 0.14) was observed. 
As shown in Table 3.3, the frequency of the pure mutant allele Pfcrt 76T was 66% 
(33/50). However, considering mixed infections with both wild type and mutant 
alleles as mutant this frequency was 90%. The frequency of the mutant Pfmdr1 86Y 
allele was 86% (43/50); including one isolate of mixed Pfmdr1 86N/Y alleles. 
Among the 45 isolates with the Pfcrt 76T mutation, 42 (93%) also carried the mutant 
Pfmdr1 86Y allele. In contrast, only one (20%) of the five parasites with the wild type 
Pfcrt 76K allele exhibited the Pfmdr1 86Y mutation. Likewise, 42 of the 43 (97.7%) 
isolates with Pfmdr1 86Y also had the mutant Pfcrt 76T allele, whereas only 3 
(42.9%) of the 7 with pfmdr1 wild type isolates exhibited Pfcrt 76T (Table 3.4). 
Whether or not the mixed infections were excluded from the analysis, the association 
between the two loci was significant (P = 0.001). 
As shown in Table 3.4, all 42 isolates carrying both, Pfcrt 76T and Pfmdr1 86Y also 
exhibited the Pfdhfr 51I and 108N mutations (P < 0.001). The frequency of the 
mutant Pfdhps 540E allele was significantly associated with Pfcrt 76T and Pfmdr1 
86Y; P = 0.001, P = 0.009, respectively. In contrast, the Pfdhps 581G variant occurred 
in these isolates in 21.4% (9/42) only. The four isolates with Pfcrt and Pfmdr1 wild 
type alleles also exhibited wild type codons for Pfdhfr and Pfdhps. The reverse, 
however, was not true since three of the eight isolates with Pfdhfr wild type alleles 
contained Pfcrt 76T, and one Pfmdr1 86Y (Table 3.4). 
There was no association between the treatment outcome and the prevalence of the 
different mutations for any of tested drug resistance genes/codons in both treatment 
arms (P = 0.5-1).  
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Table 3.3: Frequency of wild, mutant and mixed alleles of Plasmodium falciparum; chloroquine transporter (Pfcrt), multidrug  
resistance (Pfmdr1), dihydrofolate reductase (Pfdhfr) and dihydrpteroate synthetase (Pfdhps) genes, in 50 parasite isolates  
obtained from Daraweesh and Kajara, eastern Sudan 
 
 
Genotype Pfcrt  Pfmdr1   Pfdhfr gene 
 
pfdhps gene 
Codon K76T N86Y A16V N51I C59R S108N I164L S436A A437G K540E A581G A613S 
Wild 0.1 0.14 1 0.16 1 0.16 1 1 1 0.2 0.8 1 
Mutant 0.66 0.84 0 0.84 0 0.84 0 0 0 0 0.1 0 
Mixed 0.24 0.02 0 0 0 0 0 0 0 0.8 0.1 0 
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Table 3.4: Polymorphism profile of Plasmodium falciparum; chloroquine 
transporter (Pfcrt), multidrug resistance (Pfmdr1), dihydrofolate reductase 
(Pfdhfr) and dihydrpteroate synthetase (Pfdhps) genes of the 50 parasite isolates 
obtained from Daraweesh and Kajara, eastern Sudan 
Patient ID Pfcrt-76 Pfmdr1-86 Pfdhfr-51 Pfdhfr-108 Pfdhps-540 Pfdhps-581 
O7-N8 Wild Wild Wild Wild Wild Wild 
K7-O11 Wild Wild Wild Wild Wild Wild 
K14-O17 Wild Wild Wild Wild Wild Wild 
K28-O26 Wild Wild Wild Wild Wild Wild 
K4-N13 Mixed Wild Wild Wild Wild Wild 
K11-O16 Mutan Wild Wild Wild Wild Wild 
K18-N21 Mutan Wild Wild Wild Wild Wild 
A6-O10 Wild Mutan Wild Wild Mixed Mutan 
K2-N12 Mutan Mutan Mutan Mutan Wild Wild 
K27-O25 Mutan Mutan Mutan Mutan Wild Wild 
K12-N18 Mutan Mutan Mutan Mutan Wild Mutan 
OE9-O1 Mixed Mutan Mutan Mutan Mixed Wild 
F11-N4 Mixed Mutan Mutan Mutan Mixed Wild 
H4-O7 Mixed Mutan Mutan Mutan Mixed Wild 
B12-N9 Mixed Mutan Mutan Mutan Mixed Wild 
P5-N10 Mixed Mutan Mutan Mutan Mixed Wild 
K1-N11 Mixed Mutan Mutan Mutan Mixed Wild 
K19-N22 Mixed Mutan Mutan Mutan Mixed Wild 
K20-O21 Mixed Mutan Mutan Mutan Mixed Wild 
H7-O8 Mutan Mutan Mutan Mutan Mixed Wild 
B8-N1 Mutan Mutan Mutan Mutan Mixed Wild 
H18-N2 Mutan Mutan Mutan Mutan Mixed Wild 
G5-N3 Mutan Mutan Mutan Mutan Mixed Wild 
H11-O2 Mutan Mutan Mutan Mutan Mixed Wild 
A11-O4 Mutan Mutan Mutan Mutan Mixed Wild 
H13-N7 Mutan Mutan Mutan Mutan Mixed Wild 
K3-O9 Mutan Mutan Mutan Mutan Mixed Wild 
B11-N14 Mutan Mutan Mutan Mutan Mixed Wild 
K5-N15 Mutan Mutan Mutan Mutan Mixed Wild 
K6-N16 Mutan Mutan Mutan Mutan Mixed Wild 
2S1-O15 Mutan Mutan Mutan Mutan Mixed Wild 
K10-N17 Mutan Mutan Mutan Mutan Mixed Wild 
2E3-N20 Mutan Mutan Mutan Mutan Mixed Wild 
K15-O18 Mutan Mutan Mutan Mutan Mixed Wild 
K16-O19 Mutan Mutan Mutan Mutan Mixed Wild 
K17-O20 Mutan Mutan Mutan Mutan Mixed Wild 
F21-O22 Mutan Mutan Mutan Mutan Mixed Wild 
K22-N24 Mutan Mutan Mutan Mutan Mixed Wild 
K24-O23 Mutan Mutan Mutan Mutan Mixed Wild 
K25-N27 Mutan Mutan Mutan Mutan Mixed Wild 
K29-N28 Mutan Mutan Mutan Mutan Mixed Wild 
K9-O14 Mutan Mutan Mutan Mutan Not done Wild 
K26-O24 Mutan Mutan Mutan Mutan Mixed Mixed 
H21-N6 Mutan Mutan Mutan Mutan Mixed Mixed 
O1-O6 Mutan Mixed Mutan Mutan Mixed Mixed 
H17-O3 Mixed Mutan Mutan Mutan Mixed Mixed 
A7-N5 Mixed Mutan Mutan Mutan Mixed Mixed 
OE8- Mixed Mutan Mutan Mutan Mixed Mutan 
K21-N23 Mutan Mutan Mutan Mutan Mixed Mutan 
A4-O5 Mutan Mutan Mutan Mutan Mixed Mutan 
 
Mutan  = Mutan 
Mixed = presence of wild and mutant allele 
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3.2. Efficacy of artesunate plus sulfadoxine-pyrimethamine 
3.2.1. Treatment outcomes  
To evaluate efficacy of AS plus SP in Haj Yousif area, Khartoum State, a total of 118 
patients with uncomplicated falciparum malaria were enrolled in the study. Baseline 
characteristics are summarized in Table 3.5. A total of 108 patients were monitored 
for 28 days, 10 patients (8.5%) were dropped from the analysis, because of either: loss 
to follow-up (4), travel from the study area (3), self medication with other antimalarial 
during the follow up period (1), unwillingness to participate in the study (1), or death 
(1).  
 
Table 3.5: Baseline characteristics of uncomplicated falciparum malaria patients 
treated with artesunate plus sulfadoxine-pyrimethamine in Haj Yousif area, Khartoum 
State 
Characteristic  
Median ± 25th; 75th age in years  18 ± 11; 28 
Children: adults (%) 32.4: 67.6 
Male: female (%) 59.3: 40.7 
History of previous antimalarial (%) 87 
Mean ± SE body weight (kg) 46.8 ± 1.9  
Median ± 25th; 75th axillary temperature (ºC) 38.5 ± 37.9; 39.1 
Median ± 25th; 75th parasitemia (/µl) 10920 ± 4650; 20780 
Proportion with gametocytes (%) 6.5 
 
3.2.1.1. Primary outcomes 
Before PCR correction, of the 108 patients who completed follow up to day 28, 97 
patients (89.8%) had an ACPR. Overall treatment failure by day 28 was 10.2% (11). 
All treatment failures, except one, were LTF that occurred between days 14 and 28 
(Table 3.6).  
PCR corrected results using paired samples of day 0 and the day of recrudescence 
showed genetic heterogeneity (new infections) in two out of the 10 cases. In addition 
to heterogeneity, no heterogeneity was detected in the other 8 pairs, which suggested 
the presence of recrudescence together with new parasite populations. The 
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polymerase chain reaction corrected cure rate was 91.7%. No adverse events that 
could have been related to antimalarial medication were reported.  
 
Table 3.6. Crude and genotyping adjusted clinical and parasitological response of 
uncomplicated falciparum malaria to artesunate plus sulfadoxine-pyrimethamine in 
Haj Yousif area  
Number (%) Treatment outcome 
Crude PCR adjusted 
Early treatment failure 1 (0.9) 01 (0.9) 
Late clinical failure 7 (6.5) 05 (4.6) 
Late parasitological failure 3 (2.8) 03 (2.8) 
Total failures 11 (10.2) 9 (8.3) 
Adequate clinical and parasitological response (ACPR) 97 (89.8) 99 (91.7) 
Total  108 (100 ) 108 (100 ) 
 
3.2.1.2. Secondary outcomes 
Fever clearance time (median ± 25th; 75th) was 1 day ± 1; 1. All evaluated patients 
(107) except the patient classified as ETF were afebrile by day 3. Whereas 27 (25.2%) 
and one patient (4.7%) had fever on day 1 and 2, respectively (Figure 3.3).  
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Figure 3.3. Proportion of febrile malaria patients during the 28 days following 
artesunate plus sulfadoxine-pyrimethamine treatment in Haj Yousif 
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Parasite clearance time (median ± 25th; 75th) was 1±1; 1 day, 11.2% (12 of 107) of 
patients were parasitemic by day 1, and only 3.7% (4 of 107) by day 2. All the 
evaluated patients were aparasitaemic by day 3 (Figure 3.4). The day 0 median 
parasite density was 10920 P/µl (109040), it decreased to 480 P/µl (8800) by day 1 
and to 180 P/µl by day 2 (1960).  
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Figure 3.4: Proportion of patients with asexual Plasmodium falciparum 
parasitemia during 28 days following artesunate plus sulfadoxine-
pyrimethamine treatment in Haj Yousif 
  
The overall gametocyte prevalence decreased gradually during the follow up period: 
At baseline, the proportion of patients with gametocytes was 6.5% (7 of 107). Of 
these, 3 (42.9%) and 2 (28.6%) were still gametocytemic on day 7 and 14, 
respectively. No gametocytes were detected on day 21 or 28 (Figure 3.5).   
Among the patients who had no gametocytes at baseline, only one patient was 
gametocytemic on day 7. 
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Figure 3.5: Proportion of patients with Plasmodium falciparum gametocytemia 
during the 28 days following artesunate plus sulfadoxine-pyrimethamine 
treatment in Haj Yousif 
 
3.2.2. Distribution of Plasmodium falciparum dihydrofolate reductase and 
dihydropteroate synthetase haplotypes among the study population in Haj 
Yousif  
Single nucleotide polymorphisms in Pfdhfr and Pfdhps genes were determined in 86 
and 91 isolates, respectively. 
Mutations in Pfdhfr were detected at positions 51 (51I) and 108 (108N) only and in 
Pfdhps at positions 436/437 (436A/437G), 540 (540E) and 581 (581G). No 
polymorphisms were found at Pfdhfr positions 59 and 164 or at Pfdhps position 613 
(Table 3.7). In table 3.7, the Pfdhfr and Pfdhps is shown as constructed haplotypes: 
The double mutant Pfdhfr haplotype (CICNI) was the most frequent, existed in 96.5% 
(83) of the infections. While the single Pfdhfr mutant haplotype (CNCNI) was found 
in 2.3% (2) of the infections, and only one infection had the wild type Pfdhfr 
haplotype (CNCSI). In contrast, Pfdhps mutant haplotypes were detected at a low 
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frequency (9.9%), only two infections (2.2%) had more than one Pfdhps mutation, 
containing the combination of 437G/540E. Plasmodium falciparum dhps single 
mutant haplotypes was detected in 7.7% (7) of the infections.  
 
Table 3.7: Distribution of Plasmodium falciparum dihydrofolate reductase 
(Pfdhfr) and dihydropteroate synthetase (Pfdhps) haplotypes in Haj Yousif  
 
Pfdhfr 50/51/59/108/164  
(N = 86) 
Pfdhps 436/437/540/581/613 
(N = 91) 
Haplotype Frequency (N) Allele Frequency (N) 
CICNI 91.9% (79) SAKAA 90.1 (82) 
MCNI 4.7% (4) SAEAA 3.3 (3) 
CNCNI 2.3% (2) SGKAA 2.2 (2) 
CNCSI 1.2% (1) MKAA 2.2 (2) 
  SGEAA 1.1 (1) 
  SGEGA 1.1 (1) 
 
• Underline = Mutation 
Combination of the dominant double mutant Pfdhfr haplotype (CICNI) and the 
mutant Pfdhps haplotype (SGEAA) 437G/540E was detected in two isolates (2.6%), 
shown in Table 3.8. 
 
Table 3.8: Combinations of Plasmodium falciparum dihydrofolate reductase and 
dihydropteroate synthetase haplotypes among the studied population in Haj 
Yousif area (N = 76)  
 
Combination 
Pdhfr 50/51/59/108/164 + Pfdhps 436/437/540/581/613 
  
 
Frequency (Number) 
CICNI + SAKAA 82.9% (63) 
MCNI + SAKAA 5.3% (4) 
CICNI + SAEAA 3.9% (3) 
CICNI + MKAA 2.6% (2) 
CICNI + SGEGA 1.3% (1) 
CICNI + SGEAA 1.3% (1) 
CNCNI + SAKAA 1.3% (1) 
CNCSI + SAKAA 1.3% (1) 
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3.2.3. Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and 
dihydrpteroate synthetase (Pfdhps) haplotypes in relation to in vivo response to 
artesunate plus sulfadoxine-pyrimethamine 
Allelic haplotypes within Pfdhfr and Pfdhps genes were examined for their 
association with in vivo response to SP plus AS. Based on the WHO 28 day 
classification system; results are summarized in Table 3.9. No association was 
observed between Pfdhfr mutant haplotypes and treatment failure (P = 0.27), where 
the predominant Pfdhfr haplotype (CICNI) was detected in 92.2% of the ACPR and in 
85.7% of treatment failure infections. Similarly no association was found between 
Pfdhps mutant haplotypes and treatment failure. Furthermore, no association was 
observed between the combinations of Pfdhfr/Pfdhps haplotypes and treatment failure 
(P = 0.14) 
 
Table 3.9: Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and 
dihydropteroate synthetase (Pfdhps) allelic haplotypes in relation to in vivo 
response to artesunate plus sulfadoxine-pyrimethamine among patients from 
Haj Yousif  
 
Haplotype Number (%) 
 Adequate clinical 
and parasitological 
response 
Treatment failure  
 Pfdhfr   50/51/59/108/164   
CICNI 71 (92.2) 6 (85.7) 
MCNI 4 (5.2) 0 (0) 
CNCNI 1 (1.3) 1 (14.3) 
CNCSI 1 (1.3) 0 (0) 
Total (N) 77 7 
   
Pfdhps 436/437/540/581/613   
SGEAA 1 (1.2) 0 (0) 
SGEGA 0 (0) 1 (14.3) 
SGKAA 2 (2.4) 0 (0) 
MKAA 2 (2.4) 0 (0) 
SAEAA 3 (3.6) 0 (0) 
SAKAA 75 (90.4) 6 (85.7) 
Total (N) 83 7 
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3.3. Distribution of Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and 
dihydropteroate synthetase (Pfdhps) allelic haplotypes in New Halfa and Kassala 
To assess the the distribution of SP resistance marker alleles in P. falciparum in New 
Halfa and Kassala, single nucleotide polymorphisms in Pfdhfr and in Pfdhps genes 
associated with SP resistance, were detected in P. falciparum isolates from New Halfa 
(79) and from Kassala (49), and allele frequencies within the two genes were 
determined in pretreatment samples with positive ELISA results. Hundred twenty 
eight and 119 P. falciparum were examined for Pfdhfr and Pfdhp, respectively. Mixed 
genotypes and pure mutants were combined in all analysis. 
Single nucleotide polymorphisms in Pfdhfr gene were detected at codons 50; (50R), 
51; (N51I), 108; (S108N) and 59; (C59R). The overall frequency of Pfdhfr mutant 
haplotypes was high and comparable in both sites (82.3% in New Halfa and 91.8% in 
Kassala) (Table 3.10).  
Single nucleotide polymorphisms in Pfdhps gene were identified in 79 isolats from 
New Halfa and 40 from Kassala, mutations were detected at codons S436A, A437G 
and K540E. Polymorphism at codon A581G was identified only in Kassala isolates. 
(Table 3.10).  
In contrast the overall frequency of Pfdhps mutant haplotypes was significantly lower 
in New Halfa (39.2%) compared to Kassala (90%) (P = 0.000) (Table 3.10). 
No polymorphisms at Pfdhfr position 164 or Pfdhps position 613 were detected.  
Within the Pfdhfr gene, the double mutant Pfdhfr haplotype (CICNI) was the 
predominant haplotype in both sites with a frequency of 57% and 83.7% in New 
Halfa and Kassala, respectively. Plasmodium falciparum dhfr triple mutant haplotype 
(CIRNI) was rare in both sites; identified in 2 isolates each in New Halfa (2.5%) and 
Kassala (4.1%), (Table 3.10; Figure 3.6).  Single mutant haplotypes (CNCNI or 
CICSI) at positions 108 and 51 were identified in 7 (8.9%) isolates in New Halfa. 
On the other hand within Pfdhps gene, the most frequent mutant haplotype in both 
sites are the ones harboring mutations at codons 437 and 540 (SGEAA) with a 
frequency of 17.7% in New Halfa and 62.5% in Kassala. Single mutant haplotype 
(Table 3.10) was found to be most frequent in New Halfa (8.9%) than in Kassala 
(2.5%). 
Isolates harbouring quintuple mutations at Pfdhfr positions 51, 59, 108 and at Pfdhps 
positions 437 and 540 were found in 2.9% (2) and 5.9% (2) of the isolates from New 
Halfa and Kassala, respectively (Figure 3.6). 
 63
 
Table 3.10: Allelic haplotypes distribution within Plasmodium falciparum 
dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) genes 
in P. falciparum isolates from New Halfa and Kassala  
• M = mixed genotype 
• MEGA: M = AG/SG  
• MMAA: M = SG/AA or SG/SA 
• MEAA: M = AG/SG or AG/SA or SG/SA 
• MKAA: M = AA/SA 
 
 
 
 
 
Frequency (N) Haplotype 
New Halfa Kassala 
Pfdhfr 50/51/59/108/164 
CICNI 
 
57% (45) 
 
83.7% (41) 
MCNI 3.8% (3) - 
CICMI 1.3% (1) - 
CIRNI 2.5% (2) 4.1% (2) 
CIRSI 1.3% (1) - 
CNRNI - 2% (1) 
CICSI 6.3% (5) - 
MCSI 7.6% (6) - 
CNCNI 2.5% (2) - 
CNCMI - 2% (1) 
CNCSI 17.7% (14) 8.2% (4) 
Total 100% (79) 100% (49) 
 
Pfdhps 436/437/540/581/613
SGEAA 
 
17.7% (14) 
 
62.5% (25) 
SGMAA 2.5% (2) - 
AGEAA - 2.5 (1) 
SGEGA - 10% (4) 
MEGA - 5% (2) 
MMAA 2.5% (2) - 
MEAA 1.3% (1) 7.5% (3) 
MKAA 3.8% (3) - 
SAEAA 1.3% (1) 2.5% (1) 
AAMAA 1.3% (1) - 
AAEAA 1.3% (1) - 
AAKAA 7.6% (6) - 
SAKAA 60.8% (48) 10% (4) 
Total 100% (79) 100% (40) 
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Figure 3.6: Distribution of haplotypes of Plasmodium falciparum dihydrofolate 
reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes in New Halfa 
and Kassala in eastern Sudan 
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4.1. Discussion 
In Daraweesh and Kajara site; frequency of treatment failure was comparable in the 
two studied groups with 31.8% and 37.5% in CQ+DHA and CQ+S/P group, 
respectively. Although these findings are unsatisfactory in term of clinical or 
parasitological efficacy, the rate of treatment failure with the two studied 
combinations is lower than the previously reported levels with CQ monotherapy in the 
study area. Considering 28 days follow up period, previous studies on CQ efficacy in 
eastern Sudan reported 42% CQ resistance in 1989, 48% in 1990, 77% in 2004, and 
76% in 2006 (214,215,217,218). The observed treatment failure among CQ+DHA 
group suggests that addition of CQ to DHA has no advantage over DHA 
monotherapy, where recrudescence in monotherapy with artemisinin and its 
derivatives was reported (68,69). On the other hand these findings indicated SP 
treatment failure in the study area; the reported failure to CQ+SP is consistent with a 
recent study reported 31.7% failure to SP alone and 36.6% failure to CQ+SP in the 
same area (224). 
The observed faster clearance of asexual parasitaemia, and significant decrease in its 
prevalence by day 1 in CQ+DHA group compared to CQ+SP, and the lower post 
treatment gametocyte carriage in CQ+DHA group, in spite of the higher pretreatment 
levels compared to CQ+SP could be attributed to the efficacy of DHA against the 
blood stages (59) and its gametocytocidal effect (60,61). Another explanation of the 
low gametocyte carriage in CQ+DHA compared to CQ+SP regimen, might be the 
suggested inherent property of SP to increase gametocyte carriage (241,242).  
No association was observed between the detected mutations in Pfdhfr, Pfdhps, Pfcrt 
and Pfmdr1 and treatment failure to the studied combinations. However, such results 
are expected because the sample size in each treatment arm was small and the 
frequency of relevant mutations was high. 
In this study, associations between mutations that confer resistance to CQ and SP 
were explored. These results revealed a strong association between Pfcrt 76T 
(chromosome 7) and Pfmdr1 86Y (chromosome 5) as reported before in different sites 
(152,243,244,245). Inter and intragenic association of Pfdhfr and Pfdhps mutant 
codons was not seen among the parasites examined in this study, although it was 
indirectly proved in the studies where SP resistance was found to be associated with 
mutations in both genes (131,165,174). There were strong associations between the 
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mutations Pfcrt 76T, Pfmdr1 86Y, Pfdhfr 51I, Pfdhfr 108N and Pfdhps 540E, which 
convey the parasite resistance against both CQ and SP. 
The frequencies of the CQ resistance mutations Pfcrt 76T (90%) and Pfmdr1 86Y 
(86%) in the area have only slightly increased over the last 2 years from 81 to 87 and 
79%, respectively (245,246).  
Plasmodium falciparum dihydrofolate reductase 51I and 108N alleles occurred in 
more than 80% of the examined isolates. Although the frequency of Pfdhfr 108N was 
comparable with that of the Pfcrt 76T, longitudinal data proved that the rise in the 
Pfdhfr 108N allele had happened recently, unlike that of Pfmdr1 86Y and Pfcrt 76T 
(Figure 4.1).  
An unexpected finding was the association of at least five mutations (Pfcrt 76T, 
Pfmdr1 86Y, Pfdhfr 51I and 108N and Pfdhps 540E) scattered on four different 
chromosomes and incriminated in resistance to two different antimalarials, CQ and 
SP. Association between the mutations Pfcrt 76T, Pfmdr1 86Y and Pfdhfr 108N has 
been reported before from West Africa (243,247). So far, the reason for the observed 
associations between separate mutations conferring resistance to unrelated drugs is 
obscure. Remarkably in this regard, selection for high grade pyrimethamine resistance 
has been reported to be accompanied by an increased number of mutations in P. 
falciparum (248). In this study the observed association between the CQ and SP 
resistance mutations could be explained within the context of drug pressure. Where 
CQ and SP had been the first and second line antimalarial treatment for long time in 
Sudan, and both drugs are affordable and available in the local markets. 
 
Sudan has changed its national first and second line antimalarial treatment from CQ 
and SP to AS plus SP and artemether plus lumefantrine (Co-artem). However recent 
reports have indicated SP treatment failure in different parts of Sudan 
(221,222,223,225,226,249). Although some efficacy studies of AS + SP in the 
country are available (223,250,251,252,253), the debatable efficacy of SP necessitate 
additional studies for continuous monitoring the efficacy of the first line antimalarial 
regimen and the spread of SP resistance markers. 
The present study examined efficacy of AS + SP in a mesoendemic suburban malaria 
area of Khartoum, 92.6% of the infections were cured by day 28, while 7.4% showed 
a LTF response. The results were confirmed using PCR genotyping. PCR results 
showed that the LTFs were a combination of old and new infections in all recurring 
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samples. This finding has major epidemiological consequences as it reflects the 
inability of SP to protect AS and prevent new infections (a role supposed to be played 
by the partner drug in ACT) after therapy (87). The microepidemiology of resistance 
of the partner drug has to be considered in ACT. A comparable cure rate (91.2%) was 
reported in southern (Nuba Mountain) Sudan (251), cure rates to AS+SP ranging 
between 99-100% have been reported from different parts of Sudan 
(223,250,252,253). In the present study all patients became afebrile and aparasitemic 
after three days and gametocytemia was not detected in any infection by the end of 
the follow up period. The rapid elimination of parasites and clearance of fever showed 
the clinical benefit of AS, as artemisinin and its derivatives have been reported as 
potent, short acting antimalarials with rapid clinical recovery and parasite/gametocyte 
clearance times (59,60,61). The gametocytocidal ability of AS compensates the 
suggested inherent property of SP to increase gametocyte carriage (242).   
All Adverse events reported previously after treatment with ART derivatives and 
ACTs were mild and none had led to discontinuation of treatment (254,255). In spite 
the documented failure to treatment with the combination of AS with SP in Haj 
Yousif, the combination appeared to be safe and well tolerated. In addition it 
combined the benefits of rapid parasite clearance, symptoms relief and low 
gametocyte carriage associated with AS, with the longer term efficacy of SP. 
Nevertheless AS and SP combination is relatively cheap and might reduce the rate at 
which SP resistance develops. 
 
 Plasmodium falciparum dihydrofolate reductase and Pfdhps allelic haplotypes and 
their distribution in relation to treatment outcome were investigated in this study. 
Consistent with previous studies conducted in the same area (221,256) and other two 
sites in eastern Sudan (249,Osman ME et al; unpublished data); the most frequent 
Pfdhfr haplotype in the study area was Pfdhfr double mutant (CICNI), however its 
rate (91.9%) is much higher than in 2002 (79%) and in 2005 (80%) in same area 
(221,256). This might be attributed to the use SP monotherapy, and of cotrimoxazole 
(trimethoprim/sulfamethoxazole) in the study area for common bacterial infections, 
both drugs are affordable and readily available in the local market. This haplotype 
was found to be predominant in southern Sudan where the majority of parasites in the 
area harboured wild genotype (220,257). 
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In the present study no significant association was observed between treatment failure 
and the frequency of Pfdhfr mutant haplotypes (P = 0.27)), where the predominant 
Pfdhfr haplotype CICNI harbouring mutations at codons 51 and 108 is homogenously 
distributed between ACP responders (97.4%) and treatment failure groups (85.7%). 
These findings suggest that (CICNI) haplotype is insufficient to confer SP clinical 
failure, but since this Pfdhfr haplotype is supposed to be prerequisite for increased 
resistance to pyrimethamine (135,258), and taking into account that Pfdhfr mutations 
are acquired in a stepwise fashion, (131,165), further mutation in Pfdhfr, namely at 
codon 59 might lead to increased clinical failure to SP. Our findings support the 
hypothesis that resistance associated mutations in Pfdhfr gene are useful in 
monitoring progress of resistance to SP but not the current situation of clinical failure 
to SP (238,259). 
The current study confirms the previously reported poor predictive value of resistance 
related Pfdhps mutations for SP treatment failure, as 90.4% and 85.7% of the ACPR 
and treatment failure infections, respectively carrying Pfdhps wild type haplotype 
(SAKAA). The Pfdhps double mutant (437G/540E) was shown to increase the 
likelihood of treatment failure to SP when coexisted with the Pfdhfr triple mutant 
variant (157,174,175).  
However in the current study, the actual SP failure was most likely underestimated, 
because some SP resistant parasites might be cleared by the action of AS which was 
used in addition to SP, or by host immune response (79,260), where existence of 
certain degree of immunity was reported in areas with moderate transmission level 
(261). 
 
Since it is now a priority to provide baseline information on the distribution of SP 
resistance marker alleles in P. falciparum in Sudan, the frequency of Pfdhfr and 
Pfdhps mutations, associated with decreased sensitivity to SP was investigated in two 
sites in eastern Sudan; New Halfa and Kassala. Mutations at the key positions in 
Pfdhfr (C51I, C59R and S108N) and Pfdhps (S436A, A437G, K540E and A580G) 
identified in this study, were found to occur commonly in different parts of Sudan 
(220,221,249,257,258). 
The overall high frequency of Pfdhfr mutant alleles and the predominance of double 
mutant haplotype CICNI harbouring mutations at codons 51 and 108, found in both 
study sites (Table 3.10) are in consistence with the only one previous study which has 
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estimated the fequency of Pfdhfr and Pfdhps mutant haplotypes in eastern Sudan 
(249).  
The triple mutant Pfdhfr (CIRNI) at positions 51/59/108 detected in this study in New 
Halfa and Kassala was not identified before in eastern Sudan, a recent study in 
Gedaref area has found no mutation in codon 59 of Pfdhfr in all examined isolates 
(249). The very low frequency of Pfdhfr triple mutant haplotype (CIRNI), which has 
been seen in two study sites (2.5% in New Halfa and 4.1% in Kassala) (Figure 3.6), is 
in agreement with a previous study conducted in Bahr El Gazal Province, southern 
Sudan (257). Detection of this triple mutant haplotype in this part of the country is 
disturbing, since evidence of correlation between the combination of triple mutation 
in Pfdhfr at codons 51, 59 and 108 and SP treatment failure has been reported 
(157,262).  Similarly the Pfdhps haplotype carrying double mutant allele (437G/540E) 
which dominated in both study sites and frequent at a significantly lower rate in New 
Halfa (17.7%) compared to Kassala (62.5%) should be considered because it was 
thought to have a role in strengthening the association between the Pfdhfr triple 
mutant allele and SP resistance (157).  
Plasmodium falciparum with quintuple mutations at Pfdhfr positions 51, 59, 108 and 
at Pfdhps positions 437 and 540 was found at a low rate in New Halfa (2.9%) and in 
Kassala (5.9%). A strong association between this quintuple mutant variant and SP 
treatment failure has been indicated by Kublin and others in 2002 (174). According to 
the presence of P. falciparum quintuple mutant at Pfdhfr and Pfdhps key positions and 
Pfdhfr triple mutant haplotype in only a small fraction of the investigated isolates 
from both sites, SP is expected to be effective in New Half and Kassala at the 
moment.  
This study is the first to show the identification of the quintuple mutations in eastern 
Sudan. This reflects a need for continuous surveillance in the region for Pfdhfr and 
Pfdhps haplotypes, as these haplotypes have been shown to be associated with SP 
clinical failures.   
The existence of these new mutant genotypes in eastern Sudan might be triggered by 
the extensive use of SP in the study areas. Sulfadoxine-pyrimethamine is available in 
the local markets and affordable which makes self medication with SP much easier. 
The observed difference in the frequency of Pfdhps double mutant allele (437G/540E) 
between New Halfa and Kassala might not reflect a difference in SP sensitivity 
between the two areas, since the impact of this double mutant allele on SP resistance 
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depends on its coexistence with Pfdhfr triple mutant allele (51I/59R/108N), which 
exists in both sites at a comparable low rates.  
In Sudan the frequency of SNPs in Pfdhfr and Pfdhps genes, has been evaluated in 
central part; Khartoum State (221), in southern Sudan; Eastern Upper Nile and Bahr 
El Gazal (220,257) and in eastern part, Gedaref State (249). Results obtained from the 
above studies which represent different regions in Sudan; together with the current 
results are summarized in Table 4.1. The frequency of Pfdhfr mutant haplotypes is 
comparable in central and eastern Sudan where it represents more than 80% in each of 
the 4 sites (Khartoum, Gedaref, New Halfa and Kassala). In southern parts, the mutant 
Pfdhfr haplotypes existed at lower rate (40% in Bahr El Gazal and 18% in Eastern 
Upper Nile).  The double mutant Pfdhfr genotype at codons 51 and 108 was the most 
frequent Pfdhfr variant in all the investigated regions in Sudan, with much higher 
rates in central and eastern Sudan (>60%) compared to southern sites (18% and 28%). 
Triple mutant Pfdhfr haplotype which was detected in this study in New Halfa (2.5%) 
and Kassala (4.1%) eastern Sudan, was identified before in one site in southern Sudan 
(Bahr El Gazal; 3%). 
The Pfdhps (SGEAA), the major mutant haplotype in New Halfa (24%) and Kassala 
(87.5%), was identified before in southern Sudan in Bahr El Gazal at 9% frequency, 
and this study detected a lower frequency in Khartoum (1.1%). This haplotype was 
not found previously either in central or eastern Sudan. No mutant alleles within 
Pfdhps gene were reported in Upper Nile (southern Sudan), where 100% SP cure rate 
was reported in 2003 (220). 
In summary this comparison shows variation in Pfdhfr and Pfdhps allele frequencies 
by geographic location, which might be due to difference in magnitude and duration 
of SP and antifolates use in different regions.  
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Figure 4.1: Longitudinal data show the relative and stepwise rise in the 
frequency of mutant alleles, Pfcrt 76T, Pfmdr1 86Y and Pfdhfr 108N, in parasites 
collected from the same area over 10 years (1993–2003), data until 2001 was 
obtained with permission from Abdel-Muhsin and Babiker (246) 
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Table 4.1:  Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) allelic haplotypes frequency in different 
regions in Sudan 
Haplotype Southern Sudan Central Sudan Eastern Sudan 
Khartoum Pfdhfr 51/59/108/164 Eastern Upper 
Nile 
Bahr El Gazal 
2002 2004-2005 
Gedaref New Halfa Kassala 
IRNI 0 3 0 0 0 2.5 4.1 
ICNI 14 28 78.4 91.9 84 62.1 83.7 
IRSI 0 0 0 0 0 1.3 0 
NRNI 2 6 0 0 0 0 2 
ICSI 0 0 5.4 0 0 13.9 0 
NCNI 2 3 0 2.3 0 2.5 2 
MCNI 0 0 0 4.7    
Wild genotype 82 60 16.2 1.2 16 17.7 8.2 
Pfdhps 436/437/540/581/ 613       
SGEAA 0 9 0 1.1 0 20.3 62.5 
SGEGA 0 0 0 1.1 0 0 10 
AGEAA 0 0 0 0 0 0 2.5 
SAEAA 0 0 0 3.3 61 2.5 2.5 
SAEGA 0 0 0 0 18 0 0 
SAKGA 0 0 0 0 2 0 0 
SGKAA 0 0 0 2.2    
AAEAA 0 0 0 0 0 1.3 0 
AAKAA 0 44 8 0 0 7.6 0 
MEGA 0 0 0 0 0 0 5 
MMAA 0 0 0 0 0 2.5 0 
MEAA 0 0 0 0 0 1.3 7.5 
MKAA 0 0 0 2.2 0 3.8 0 
Wild genotype 100 47 92 90.1 18 60.8 10 
 
● M = mixed genotype ● MMAA: M = SG/AA or SG/SA ● MKAA: M = AA/SA 
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4.2. Conclusions: 
 
● High failure rate to both antimalarial drug combinations containing CQ and SP (CQ 
plus DHA and CQ plus SP) used in Gedaref State. This is probably attributed to the 
high frequency of mutations in resistance genes for CQ and SP in eastern Sudan, and 
supported the withdrawal of both drugs.   
 
● Strong association between Pfcrt 76T, Pfmdr1 86Y, Pfdhfr 51I, Pfdhfr 108N and 
Pfdhps 540E, which are located on four different chromosomes, and conferring 
resistance against two structurally and functionally unrelated drugs, CQ and SP was 
demonstrated. This association is probably due to common use of the two drugs and 
co-selection of the above resistant alleles  
 
● The 7.4% failure to AS plus SP and the high frequency of SP resistance marker 
alleles reported in Khartoum area is alarming, since recently WHO recommended that 
a change of first line treatment should be initiated if the total failure rate exceeds 10%. 
 
● This study is the first to identify the quintuple mutations in Pfdhfr/Pfdhps genes 
(CIRNI/SGEAA) in Sudan, and to identify the triple mutant Pfdhfr (CIRNI) and the 
double mutant Pfdhps haplotype (SGEAA) in eastern Sudan. The existence of these 
new mutant genotypes is disturbing. 
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4.3. Recommendations: 
 
● Elaborate studies monitoring the efficacy of AS plus SP in different parts of the 
Sudan are needed.  
 
● Different antimalarial drug combinations should be assessed to provide future 
effective and affordable alternatives for the treatment of uncomplicated malaria in 
Sudan. 
 
● Spatial, longitudinal monitoring of SP resistance markers is needed in Sudan to 
provide data to guide future policies for treatment of malaria in both countries. 
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Appendix I 
Case Report Form 
Antimalarial Drug Combinations 
 
 
Serial number: …... 
 
Study Site: 
  
Health facility's name: 
…………..... 
Town/Village: ……………... State: ………...... 
 
Patient: 
 
 
 
 
 
 
Identity number: ….  Full Name: ………………….. Age (Years): …. Sex: (M/F): …… 
Weight (kg): ..... Name of guardian: ……………… Home Address: …………………… 
……………………………………... 
 
Antimalarial drugs: 
Combination: …………………………. 
 
 
Expiry date: ………….... 
 
 
Total dose (mg): ...... 
Previous intake:  
(Y/N/Unknown): ………... 
 
Drug: …………… 
 
Date: ………...….. 
 
Total dose (mg): ... 
 
 
 
 
Complaints 
Day 0 1 2 3 7 14 21 28 Any other 
Day (Day:….) 
Date          
Headache          
Fever          
Sweating          
Shivering          
Bitter taste          
Nausea          
Vomiting          
Diarrhea          
Cough          
Abominal pain          
Other 
complaints 
         
If others 
specify 
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Serial number: …... 
Study Site:   
Health facility's name: …………..... Town/Village:………………... State: …………...
Patient:  
 
 
 
 
 
Identity number: ….. Full Name: ………………………………………. 
 
Antimalarial drugs:  
 
Combination: ……………………………. 
  
 
Day 0 1 2 3 7 14 21 28 Day (…) 
Date          
Danger sign (Y/N)          
History of fever last 24 
hours (Y/N) 
         
Axillary temperature 
(ºC) 
         
Diagnosis (+ve/-ve)          
A sexual parasite count 
/ 200 WBCs 
         
Gametocytes (P/A)          
Sexual parasite count / 
1000 WBCs 
         
Treatment (mg/kg)          
Concomtant treatment          
Possible side effects of 
antimalarials 
         
 
Overall assessment: 
● Early treatment failure (ETF) □ 
● Late clinical failure (LCF) □ 
● Late parasitological failure (LPF ) □ 
● Adequate clinical and parasitological response (ACPR) □ 
● Withdrawn □ 
● Loss to follow up □ 
 
Day of assessment: ……   Reason for withdrawn: ………….... 
Comments: …………………………………………………….......   
